<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83205</article-id><article-id pub-id-type="doi">10.7554/eLife.83205</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-292107"><name><surname>Chen</surname><given-names>Holly Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-292109"><name><surname>Swaroop</surname><given-names>Manju</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-292116"><name><surname>Papal</surname><given-names>Samantha</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9417-6215</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-292110"><name><surname>Mondal</surname><given-names>Anupam K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-306995"><name><surname>Song</surname><given-names>Hyun Beom</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3500-2984</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-306996"><name><surname>Campello</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292108"><name><surname>Tawa</surname><given-names>Gregory J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292111"><name><surname>Regent</surname><given-names>Florian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0003-2716-1584</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292112"><name><surname>Shimada</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-292115"><name><surname>Nagashima</surname><given-names>Kunio</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292113"><name><surname>de Val</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-292114" deceased="yes"><name><surname>Jacobson</surname><given-names>Samuel G</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="fn1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-64320"><name><surname>Zheng</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1034-0757</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-62419"><name><surname>Swaroop</surname><given-names>Anand</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1975-1141</contrib-id><email>swaroopa@nei.nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pw6fb54</institution-id><institution>National Therapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, National Institutes of Health</institution></institution-wrap><addr-line><named-content content-type="city">Rockville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v6m3209</institution-id><institution>Electron Microscopy Laboratory, National Cancer Institute, Center for Cancer Research, Leidos Biomedical Research, Frederick National Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">Frederick</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Fu</surname><given-names>Zhongjie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, United States</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Physiology, Keio University School of Medicine, Tokyo, Japan</p></fn><fn fn-type="fn" id="fn1"><label>#</label><p>Deceased</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>28</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83205</elocation-id><history><date date-type="received" iso-8601-date="2022-09-02"><day>02</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-23"><day>23</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-09-18"><day>18</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.14.22279917"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83205-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83205-figures-v2.pdf"/><abstract><p>Ciliopathies manifest from sensory abnormalities to syndromic disorders with multi-organ pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain photoreceptor survival, we performed an unbiased, high-throughput screening of over 6000 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem cells (iPSC) of <italic>rd16</italic> mouse, which is a model of Leber congenital amaurosis (LCA) type 10 caused by mutations in the cilia-centrosomal gene <italic>CEP290</italic>. We identified five non-toxic positive hits, including the lead molecule reserpine, which maintained photoreceptor development and survival in <italic>rd16</italic> organoids. Reserpine also improved photoreceptors in retinal organoids derived from induced pluripotent stem cells of <italic>LCA10</italic> patients and in <italic>rd16</italic> mouse retina in vivo. Reserpine-treated patient organoids revealed modulation of signaling pathways related to cell survival/death, metabolism, and proteostasis. Further investigation uncovered dysregulation of autophagy associated with compromised primary cilium biogenesis in patient organoids and <italic>rd16</italic> mouse retina. Reserpine partially restored the balance between autophagy and the ubiquitin-proteasome system at least in part by increasing the cargo adaptor p62, resulting in improved primary cilium assembly. Our study identifies effective drug candidates in preclinical studies of <italic>CEP290</italic> retinal ciliopathies through cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal neurodegeneration.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Leber congenital amaurosis (LCA) is an inherited disease that affects the eyes and causes sight loss in early childhood, which generally gets worse over time. Individuals with this condition have genetic mutations that result in the death of light-sensitive cells, known as photoreceptors, in a region called the retina at the back of the eye. Patients carrying a genetic change in the gene CEP290 account for 20-25% of all LCA.</p><p>At present, treatment options are only available for a limited number of patients with LCA. One option is to use small molecules as drugs that may target or bypass the faulty processes within the eye to help the photoreceptors survive in many different forms of LCA and other retinal diseases. However, over 90% of new drug candidates fail the first phase of clinical trials for human diseases. This in part due to the candidates having been developed using cell cultures or animal models that do not faithfully reflect how the human body works.</p><p>Recent advances in cell and developmental biology are now enabling researchers to use stem cells derived from humans to grow retina tissues in a dish in the laboratory. These tissues, known as retinal organoids, behave in a more similar way to retinas in human eyes than those of traditional animal models. However, the methods for making and maintaining human retinal organoids are time-consuming and labor-intensive, which has so far limited their use in the search for new therapies.</p><p>To address this challenge, Chen et al. developed a large-scale approach to grow retinal organoids from <italic>rd16</italic> mutant mice stem cells (which are a good model for LCA caused by mutations to CEP290) and used the photoreceptors from these organoids to screen over 6,000 existing drugs for their ability to promote the survival of photoreceptors. The experiments found that the drug reserpine, which was previously approved to treat high blood pressure, also helped photoreceptors to survive in the diseased organoids. Reserpine also had a similar effect in retinal organoids derived from human patients with LCA and in the <italic>rd16</italic> mice themselves.</p><p>Further experiments suggest that reserpine may help patients with LCA by partially restoring a process by which the body destroys and recycles old and damaged proteins in the cells. The next steps following on from this work will be to perform further tests to demonstrate that this use of reserpine is safe to enter clinical trials as a treatment for LCA and other similar eye diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>organoid</kwd><kwd>drug discovery</kwd><kwd>retinal degeneration</kwd><kwd>human</kwd><kwd>induced pluripotent stem cells</kwd><kwd>autophagy</kwd><kwd>Primary Cilia</kwd><kwd>Ciliopathy</kwd><kwd>retina</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>Z01EY000546</award-id><principal-award-recipient><name><surname>Swaroop</surname><given-names>Anand</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>Z01EY000450</award-id><principal-award-recipient><name><surname>Swaroop</surname><given-names>Anand</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>ZIATR000018-06</award-id><principal-award-recipient><name><surname>Zheng</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>High-throughput screening of over 6000 drugs using cells and retina tissue with a CEP290 ciliopathy mutation identified a small molecule, reserpine, which enhanced photoreceptor survival in retinal organoids and in a mouse disease model by partially restoring balance in proteostasis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Once considered vestigial, the primary cilium has emerged as a key microtubule-based organelle that senses the external environment and modulates diverse signaling pathways in multiple tissues. Aberrant cilium biogenesis and/or ciliary transport and functions lead to numerous diseases, collectively termed ciliopathies, which manifest from sensory abnormalities to syndromic disorders with multi-organ pathologies including aberrant kidney morphogenesis, brain malformation, and congenital retinal degeneration (<xref ref-type="bibr" rid="bib85">Reiter and Leroux, 2017</xref>). The mammalian retina is an extension of the central nervous system that is specialized for vision (<xref ref-type="bibr" rid="bib65">London et al., 2013</xref>). The visual information is captured by rod and cone photoreceptors, integrated and processed by interneurons, and transmitted to the cortex through the retinal ganglion cells. Inability of the retinal photoreceptors to detect and/or transmit light-triggered signals is a major cause of vision impairment in retinal and macular degenerative diseases (<xref ref-type="bibr" rid="bib105">Veleri et al., 2015</xref>; <xref ref-type="bibr" rid="bib114">Wright et al., 2010</xref>; <xref ref-type="bibr" rid="bib108">Verbakel et al., 2018</xref>). Mutations in over 200 genes can lead to inherited retinal diseases (IRDs) (RetNet, <ext-link ext-link-type="uri" xlink:href="https://sph.uth.edu/retnet/">https://sph.uth.edu/retnet/</ext-link>), with a combined prevalence of 1/3–4000 individuals (<xref ref-type="bibr" rid="bib108">Verbakel et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Hanany et al., 2020</xref>). Among them, up to 20% of IRD-causing genes are involved in primary cilium biogenesis or functions (<xref ref-type="bibr" rid="bib121">Zelinger and Swaroop, 2018</xref>). Due to extensive clinical and genetic heterogeneity, high inter- and intra-family variability, and incomplete penetrance (<xref ref-type="bibr" rid="bib36">Farrar et al., 2017</xref>), treatment options for IRD are limited (<xref ref-type="bibr" rid="bib39">Garafalo et al., 2020</xref>). Only one gene therapy drug is currently approved by FDA for Leber congenital amaurosis (LCA, MIM204000) caused by <italic>RPE65</italic> mutations (<xref ref-type="bibr" rid="bib76">Pierce and Bennett, 2015</xref>). While the initial clinical outcomes were promising, the long-term data of this gene therapy drug are less encouraging (<xref ref-type="bibr" rid="bib40">Gardiner et al., 2020</xref>). Furthermore, the development of individualized gene therapy protocols for divergent mutations in a multitude of genes for rare IRDs would be time-consuming, expensive, and labor-intensive (<xref ref-type="bibr" rid="bib98">Tambuyzer et al., 2020</xref>). Thus, gene-agnostic paradigms are being developed for retinal and macular diseases using model organisms and/or stem cell-based approaches (<xref ref-type="bibr" rid="bib91">Scholl et al., 2016</xref>). Small-molecule or antibody drugs represent a relatively affordable and scalable option (<xref ref-type="bibr" rid="bib98">Tambuyzer et al., 2020</xref>). However, over 90% of drug candidates fail in Phase I clinical trials due to the lack of effective model systems which faithfully recapitulate the pathophysiology of human diseases (<xref ref-type="bibr" rid="bib45">Horvath et al., 2016</xref>). The limited number of cells in the retina and challenges in the maintenance of primary retinal cultures have also hindered the progress of therapeutic development.</p><p>LCA is a clinically severe and genetically heterogeneous group of IRDs, leads to vision loss in early childhood (<xref ref-type="bibr" rid="bib25">Cremers et al., 2018</xref>). <italic>LCA10</italic> caused by mutations in the cilia-centrosomal gene <italic>CEP290</italic> (also called <italic>NPHP6</italic>) is one of the most common types, accounting for over 20% of patients (<xref ref-type="bibr" rid="bib28">den Hollander et al., 2008</xref>). Mutations in <italic>CEP290</italic> exhibit pleiotropy with phenotypes ranging from LCA (affecting vision and other sensory systems) to nephronophthisis, and Joubert and Meckel syndromes involving multiple organ systems (<xref ref-type="bibr" rid="bib90">Sayer et al., 2006</xref>; <xref ref-type="bibr" rid="bib104">Valente et al., 2006</xref>; <xref ref-type="bibr" rid="bib66">McEwen et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Coppieters et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Drivas et al., 2015</xref>). The large 290 kDa centrosome-cilia protein CEP290 is ubiquitously expressed and localized to the Y-links of the transition zone of primary cilia, where it acts as a hub for connecting major protein complexes and likely performs a gating function (<xref ref-type="bibr" rid="bib90">Sayer et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Craige et al., 2010</xref>; <xref ref-type="bibr" rid="bib80">Rachel et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Drivas et al., 2013</xref>). The <italic>rd16</italic> mouse carries an in-frame deletion in the myosin tail of CEP290, which causes a malformed connecting cilium (equivalent to the transition zone) and rudimentary outer segment (the primary cilium of photoreceptor) structure, leading to rapid degeneration of photoreceptors (<xref ref-type="bibr" rid="bib13">Chang et al., 2006</xref>; <xref ref-type="bibr" rid="bib81">Rachel et al., 2015</xref>). Additional studies have also demonstrated the critical role of CEP290 in cilia biogenesis (<xref ref-type="bibr" rid="bib31">Drivas et al., 2013</xref>; <xref ref-type="bibr" rid="bib103">Tsang et al., 2008</xref>; <xref ref-type="bibr" rid="bib3">Barbelanne et al., 2015</xref>; <xref ref-type="bibr" rid="bib115">Wu et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Prosser et al., 2022</xref>). Thus, <italic>LCA10</italic> is considered a retinal ciliopathy caused by hypomorphic mutations (<xref ref-type="bibr" rid="bib27">den Hollander et al., 2006</xref>; <xref ref-type="bibr" rid="bib19">Cideciyan et al., 2007</xref>) that eliminate some functions of CEP290 (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>). Vision impairment in early childhood of <italic>LCA10</italic> patients imposes a considerable burden on families and society (<xref ref-type="bibr" rid="bib62">Leroy et al., 2021</xref>). Notably, these patients demonstrate sparing of the foveal cones even at late stages of life, providing an attractive target for therapy (<xref ref-type="bibr" rid="bib20">Cideciyan et al., 2011</xref>). Gene replacement using an AAV vector is difficult because of the large coding region of <italic>CEP290</italic>. Thus, other strategies including antisense oligonucleotides are currently under investigation (<xref ref-type="bibr" rid="bib21">Collin et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Gerard et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Burnight et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Dooley et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Dulla et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Kim et al., 2018</xref>). However, no approved treatment is currently available for alleviating vision loss due to CEP290 defects.</p><p>Generation of three-dimensional tissue organoids from induced pluripotent stem cells (iPSCs) (<xref ref-type="bibr" rid="bib71">Nakano et al., 2012</xref>; <xref ref-type="bibr" rid="bib89">Sasai, 2013</xref>) has revolutionized biological and disease-modeling investigations and created opportunities for high-throughput screening (HTS) to design novel treatment paradigms (<xref ref-type="bibr" rid="bib113">Welsbie et al., 2017</xref>). Further refinements of human retinal organoid culture protocols have permitted high efficiency and yield, developmental staging, and higher reproducibility (<xref ref-type="bibr" rid="bib124">Zhong et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Capowski et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Kaya et al., 2019</xref>; <xref ref-type="bibr" rid="bib84">Regent et al., 2022</xref>). Biogenesis of diverse cell types in retinal organoid cultures largely recapitulates structural and temporal development of in vivo human retina and can display intrinsic light responses mimicking those of primate fovea (<xref ref-type="bibr" rid="bib88">Saha et al., 2022</xref>; <xref ref-type="bibr" rid="bib23">Cowan et al., 2020</xref>; <xref ref-type="bibr" rid="bib95">Sridhar et al., 2020</xref>). Patient iPSC-derived human retinal organoids demonstrate disease-associated phenotypes and are being used to evaluate various therapeutic approaches (<xref ref-type="bibr" rid="bib6">Bell et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Kruczek and Swaroop, 2020</xref>). However, long and tedious generation protocols spanning 150+ days, inherent variability, and lack of compatible HTS assays still pose challenges to the application of human retinal organoids for developing therapies (<xref ref-type="bibr" rid="bib96">Struzyna and Watt, 2021</xref>).</p><p>In this study, we aimed to establish a reliable drug discovery pipeline using an organoid-based HTS platform with the goal to identify drug candidates for maintaining photoreceptor survival in retinopathies, focusing initially on <italic>LCA10</italic>. For primary HTS of over 6000 bioactive small molecules, we designed survival assays using <italic>rd16</italic> mouse iPSC-derived retinal organoids, which showed compromised photoreceptor development and viability. An FDA-approved small molecule drug reserpine was identified as an efficacious lead compound, which also enhanced photoreceptor development/survival in <italic>LCA10</italic> patient iPSC-derived retinal organoids as well as in the <italic>rd16</italic> retina in vivo. Transcriptomic analyses of drug-treated patient organoids indicated modulation of cell survival pathways including p53 and proteostasis by reserpine. Further examination validated the mis-regulation of autophagy in patient organoids and <italic>rd16</italic> retina and demonstrated partial restoration of proteostasis and improved ciliogenesis after reserpine treatment. Our study thus establishes a cross-species drug discovery pipeline using organoid-based HTS and identifies a repurposing drug candidate for maintaining photoreceptor survival in <italic>LCA10</italic> patients. As the action mechanisms of reserpine are partially through the modulation of proteostasis, which could be a common pathological impact of ciliopathies, reserpine, and its derivatives could potentially serve as an effective treatment for patients with other retinal ciliopathies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Establishment of an organoid-based HTS platform</title><p>We designed an unbiased HTS assay to identify drug candidates that might improve photoreceptor development and/or survival. For a primary screen, we chose mouse retinal organoids because of a much shorter photoreceptor differentiation time and efficient generation of rudimentary outer segments using our modified HIPRO protocol (<xref ref-type="bibr" rid="bib15">Chen et al., 2016a</xref>). We decided to use a karyotypically normal iPSC line derived from the <italic>Nrl</italic>-GFP containing <italic>rd16</italic> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), which expresses green fluorescent protein (GFP) in all rods and carries an in-frame deletion in the myosin tail homology domain of CEP290 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). The <italic>rd16</italic> mice are a model of photoreceptor degeneration observed in <italic>LCA10</italic> patients (<xref ref-type="bibr" rid="bib13">Chang et al., 2006</xref>). The iPSC lines derived from <italic>rd16</italic> mice displayed similar morphology, proliferation rate, and stem cell properties as those derived from the wild-type (WT) (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>). WT and <italic>rd16</italic> retinal organoids also showed comparable morphology at the early stages of differentiation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, at later stages, rod photoreceptors in <italic>rd16</italic> organoids displayed aberrant morphology, with malformed or missing ciliary axoneme, connecting cilium and ciliary rootlets (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). We then performed flow cytometry analyses to evaluate the differentiation of GFP+ rod photoreceptors in the <italic>rd16</italic> organoid cultures, with the goal to identify quantifiable phenotypes for HTS. The <italic>rd16</italic> organoids demonstrated as much as 50% lower organoid viability and almost 60% fewer GFP+ rod photoreceptors at day (D) 32 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), the end stage of differentiation in mouse retinal organoids.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Drug discovery pipelines to identify drug candidates.</title><p>(<bold>A</bold>) Morphology of <italic>Nrl</italic>-GFP wild-type (WT) and <italic>rd16</italic> retinal organoids differentiated from mouse-induced pluripotent stem cells (iPSC) at various differentiation time points. (<bold>B</bold>) Flow cytometry analysis of GFP+ rod photoreceptors and viability at different developmental stages. Each data point summarized at least three batches of independent experiments, each of which included at least 10 organoids. One-way ANOVA was performed to compare the %GFP+ cells and viability of organoids from four different cell lines. *p&lt;0.05; **p&lt;0.01. (<bold>C</bold>) Fluorescent images of dissociated day (<bold>D</bold>) 28 WT and <italic>rd16</italic> cells stained by 4',6-diamidino-2-phenylindole (DAPI) and anti-GFP antibody. (<bold>D</bold>) Schematic outline of the drug discovery strategy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Karyotypes of induced pluripotent stem cell lines.</title><p>(<bold>A</bold>) Mouse. (<bold>B</bold>) Human. Cells were prepared for G-band stain. Fifteen unique metaphases were analyzed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Phenotypes of retinal organoids differentiated from induced pluripotent stem cells of <italic>Nrl</italic>-GFP <italic>rd16</italic> mice.</title><p>(<bold>A</bold>) Deletion of myosin tail homology domain of the CEP290 protein in <italic>rd16</italic> mice compared to the wild-type (WT). (<bold>B</bold>) Morphology of induced pluripotent stem cells (iPSC) colonies, (<bold>C</bold>) proliferation rate of iPSCs, and (<bold>D</bold>) photoreceptor primary cilium of organoids were compared between WT and <italic>rd16</italic>. (<bold>E</bold>) Timeline of the key differentiation events in mouse organoids and primary screens. Images were representative of at least three independent experiments, each of which had at least three organoids.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig1-figsupp2-v2.tif"/></fig></fig-group><p>The phenotypes in GFP+ <italic>rd16</italic> rod photoreceptors permitted the development of an HTS screening platform to identify bioactive small-molecule candidates for augmenting rod cell differentiation and/or survival (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). To avoid the impact of organoid variability on drug effects, we dissociated <italic>rd16</italic> organoids into single cells at D25 and performed the treatment using two-dimensional cultures from D26 to D28. These cultures recapitulated the phenotypes detected in non-dissociated organoids, and <italic>rd16</italic> cells displayed reduced viability and fewer GFP+ rod cells at D28 compared to the WT (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>Our drug discovery pipeline is illustrated in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. In the primary screens, <italic>rd16</italic> retinal organoid-derived cells were treated with over 6000 small molecules; of these, 114 compounds revealed higher GFP signal intensity, indicating a positive effect on rod photoreceptor survival. We then eliminated the compounds that showed toxicity or autofluorescence even in the absence of GFP expression (false positives). Fourteen small molecule compounds were then selected for further screening to identify a lead compound.</p></sec><sec id="s2-2"><title>Selection of the lead compound</title><p>We then treated <italic>rd16</italic> retinal organoids with the 14 selected small molecules in a secondary assay, which started at D22 and lasted for three days to maximize the drug effect without causing toxicity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). WT, untreated, and treated <italic>rd16</italic> organoids were harvested at D29 to allow a sufficient period for the restoration of photoreceptors. The lead compound was selected based on the efficacy of the small molecule drugs to improve photoreceptor development and/or survival. Immunostaining of rhodopsin and S-opsin, markers of rod and cone photoreceptors respectively, was performed to quantify the drug effect (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Rhodopsin is highly expressed and polarized to the apical side of rod photoreceptors in the neural retina of WT organoids. In contrast, <italic>rd16</italic> photoreceptors exhibited lower expression of rhodopsin, and the polarity was considerably diminished. Two of the compounds, B05 and to some extent B03, were able to enhance rhodopsin expression, with B05 improving the polarity of expression in the neural retina as well. We note that S-cone photoreceptors are difficult to be maintained in mouse organoid culture (<xref ref-type="bibr" rid="bib29">DiStefano et al., 2018</xref>); nonetheless, compounds B01 and B05 were able to augment the expression and polarity of S-opsin. Three of the 5 compounds (B01, B03, B05) that showed no toxicity revealed a dramatic increase in rod and/or cone photoreceptors in D29 <italic>rd16</italic> organoids (<xref ref-type="fig" rid="fig2">Figure 2C</xref>); of these, B05 was the most effective molecule and chosen as the lead compound. Interestingly, the other four molecules (B01-B04) were found to be derivatives of B05, further validating our results. B05 was identified as reserpine, a small-molecule drug that has been approved by the FDA for the treatment of hypertension and schizophrenia (<xref ref-type="bibr" rid="bib2">Armitage et al., 1956</xref>; <xref ref-type="bibr" rid="bib48">Kalliomäki and Kasanen, 1969</xref>), thereby holding a potential for drug repurposing (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Identification of reserpine as the lead compound.</title><p>(<bold>A</bold>) Timeline for hit validation in <italic>rd16</italic> retinal organoids. (<bold>B</bold>) Immunostaining of rod cell marker rhodopsin (RHO, green) and cone cell marker S-opsin (OPN1SW, red) in wild-type (WT) and <italic>rd16</italic> organoids treated with non-toxic positive hits (B01–B05). Drug vehicle dimethylsulfoxide (DMSO) was used as a control. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three independent experiments, each of which had at least three organoids. (<bold>C</bold>) Bee swarm plots show the quantification of fluorescence intensity of rhodopsin (upper) and S-opsin (lower) staining in the validation. The shape of the plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. The pink dash line shows the mean fluorescence intensity of DMSO-treated organoids. The plot summarizes at least three independent experiments with at least three organoids in each batch. One-way ANOVA followed by the Bonferroni test was performed. *p&lt;0.05; **p&lt;0.01. (<bold>D</bold>) Chemical structure depiction of the selected lead compound reserpine.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title>Validation of reserpine on <italic>LCA10</italic> patient organoids</title><p>To further examine the efficacy of the lead compound reserpine, we utilized iPSC-derived retinal organoids from a previously-reported <italic>LCA10</italic> family (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>), which comprised of a heterozygous unaffected mother (referred to as control henceforth) and two affected compound heterozygous children (LCA-1 and LCA-2; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>). Immunoblot analysis revealed a profound reduction of full-length CEP290 in patient organoids compared to controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Defects in rod development and outer segment biogenesis were evident in patient organoids from D120 onwards, as revealed by the near loss of connecting cilium marker ARL13B and absence or mislocalization of rod-specific protein rhodopsin (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). In concordance with the observation of retained central cones in <italic>LCA10</italic> patients, cone photoreceptors were only slightly compromised even at a late stage of differentiation in patient organoids.</p><p>Given that photoreceptor, outer segment biogenesis begins around D120 in organoids (<xref ref-type="bibr" rid="bib49">Kaya et al., 2019</xref>) and aberrant phenotypes in patient organoids were detectable at this stage (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), reserpine was added to patient organoids at D107 at a concentration of 10 µM, 20 µM, or 30 µM based on the EC<sub>50</sub> (half maximal effective concentration) in the primary screens (16.7 µM) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We could detect improved connecting cilium immunostaining and rod development as early as D125 with the addition of 30 µM reserpine (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Even using the lowest tested dose (10 µM), we observed more polarized rhodopsin and connecting cilium at the apical side of photoreceptors in treated patient organoids, demonstrating a favorable effect of the drug (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Although variations in drug effects on organoids derived from the two patients could be observed, reserpine treatment significantly increased the fluorescence intensity of rhodopsin in retinal organoids derived from two patients (<xref ref-type="fig" rid="fig3">Figure 3B, C</xref>), suggesting an improvement of rod photoreceptor development. To avoid clonal variation, we also tested reserpine on another clone of each patient. Although statistically non-significant, these retinal organoids showed an obvious positive trend of rhodopsin staining upon reserpine treatment (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B, C</xref>). Such differences could be attributed to variability in response to dose and/or treatment windows of retinal organoids derived from various iPSC lines. We then performed transmission electron microscopy to uncover additional structural details of the primary cilium in photoreceptors of patient organoids after treatment. Reserpine increased the percentage of mother centrioles harboring ciliary vesicles in LCA-1 patient organoids (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>), which were reportedly missing in a substantial fraction of LCA photoreceptors (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>). LCA-2 organoids demonstrated almost 50% more elongated ciliary axonemes after reserpine treatment though ciliary vesicles were hardly noticed. Quantification of the length of the ciliary axoneme indicated a significant increase in both patient organoids after treatment (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Notably, well-organized disc-like structures could be distinguished in treated samples (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B</xref>), suggesting a positive impact of reserpine treatment on photoreceptor primary cilium development.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect of reserpine (RSP) on <italic>LCA10</italic> patient retinal organoids.</title><p>(<bold>A</bold>) Timeline for RSP treatments and harvest of patient organoids. (<bold>B</bold>) Immunostaining of rhodopsin (RHO, green) and ARL13B (red). Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three independent experiments, each of which had at least three organoids. (<bold>C</bold>) Bee swarm plots show the quantification of fluorescence intensity of rhodopsin staining. The shape of the plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. The plot summarizes at least three independent experiments with at least one image quantified in each batch. Unpaired <italic>t</italic>-test was performed to compare untreated and treated groups. *p&lt;0.05. (<bold>D</bold>) Transmission electron microscopy analysis of control, untreated, and treated patient organoids. Arrowheads indicate relevant staining. (<bold>E</bold>) Quantification of the number of the ciliary vesicles, elongated ciliary axoneme, and aberrant cilia (left) as well as the length of the primary cilia (right) in untreated and RSP-treated patient organoids. Aberrant cilia were defined as docked mother centrioles without ciliary vesicles or elongated ciliary axoneme. The data summarized at least four batches of independent experiments, each of which has at least two organoids and seven docked mother centrioles. The shape of the bee swamp plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. Unpaired <italic>t</italic>-test was performed to compare untreated and treated groups. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Genotype and phenotype of the <italic>CEP290</italic>-LCA family in this study.</title><p>(<bold>A</bold>) Genotypes of the subjects including a heterozygous but phenotypically normal control and two <italic>CEP290</italic>-LCA patients. (<bold>B</bold>) Location of the stop codons caused by point mutations in <italic>CEP290</italic>-LCA patients. (<bold>C</bold>) Western blot analysis of CEP290 in D200 control and patient retinal organoids. Images were representative of at least three independent experiments, each of which had at least three organoids. GAPDH was used as a loading control. (<bold>D</bold>) Immunostaining of. rhodopsin (green) and ARL13B (red) in the left panel as well as rhodopsin (magenta), S-opsin (red) and L/M-opsin (green) in the right panel. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three independent experiments, each of which had at least three organoids.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of CEP290.</title><p>The size of the protein ladders, CEP290, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of GAPDH.</title><p>The size of the protein ladders, GAPGH, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig3-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effect of reserpine at various conditions in <italic>CEP290</italic>-LCA retinal organoids.</title><p>Rod cell marker rhodopsin (RHO, green) and ciliary marker ARL13B (red) were shown in (<bold>A</bold>) LCA1 organoids treated with 30 μM reserpine (RSP) at differentiation day (<bold>D</bold>) 125 (upper) and with 10 μM RSP at D150 (lower) and (<bold>B</bold>) organoids differentiated from clone C of LCA1 (upper) and clone F of LCA2 (lower) at D150. (<bold>C</bold>) Quantification of fluorescence intensity of rhodopsin staining. The shape of the Bee Swamp plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. The plot summarizes at least three independent experiments with at least one image quantified in each batch. Unpaired <italic>t</italic>-test was performed to compare untreated and treated groups. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Transmission electron microscopy analyses of control, and untreated and treated <italic>CEP290</italic>-LCA retinal organoids.</title><p>(<bold>A</bold>) Morphology of photoreceptor primary cilium. (<bold>B</bold>) Stacks of disc-like structures observed in treated patient organoids. Arrowheads indicate relevant structures.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Various cell types in reserpine (RSP)-treated <italic>CEP290</italic>-LCA retinal organoids.</title><p>Immunostaining of structural or cell type-specific markers including those for L/M cones (OPN1LMW, green), S-cones (OPN1SW, red), ribbon synapses (BASSOON, red), presynaptic vesicles (SYNAPTOPHYSIN, green), bipolar cells (CHX10, green; PKCα, red), Müller glia (CRALBP, green; GFAP, red). Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three independent experiments, each of which had at least three organoids.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig3-figsupp4-v2.tif"/></fig></fig-group><p>We note that reserpine reportedly interferes with the sympathetic nervous system by inhibiting the transport of neurotransmitters into presynaptic vesicles (<xref ref-type="bibr" rid="bib7">Bernstein et al., 2014</xref>); yet, even at 30 µM, no adverse effect was detected on the development of cone photoreceptors, ribbon synapses, presynaptic vesicles, bipolar cells, and Müller glia in treated patient organoids (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>).</p></sec><sec id="s2-4"><title>Implication of cell survival and proteostasis pathways in reserpine-treated organoids</title><p>To elucidate the mechanism of action of reserpine and to gain insights into photoreceptor cell death in <italic>LCA10</italic>, we performed RNA-seq analyses of control and patient retinal organoids. The organoids were harvested right after the treatment with 30 µM reserpine at D150 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Consistent with the moderate response of LCA-2 patient organoid to reserpine (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>), we did not identify sufficient significantly differentially expressed (DE) genes between untreated and treated groups of LCA-2 for downstream analyses (data not shown) and thereby focused only on LCA-1. Principal component analysis (PCA) revealed substantial alterations in patient organoid transcriptome compared to control and after reserpine treatment (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The largest principal component PC1 accounted for up to 36.2% of the total variation and is likely due to the drug treatment. PC2 explained another 21% of the total variation and seemed to be mainly contributed by the disease status. Notably, the reserpine-treated group was closer to the control compared to the untreated group in PC2. A total of 355 genes were significantly differentially expressed between untreated and treated organoids at thresholds of 5% FDR and twofold change (<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). Consistent with the PCA plot, heatmap analysis indicated that DE genes in treated patient organoids showed a relative transcriptomic shift from the untreated group toward the control ones (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). However, compared to the controls, most of the downregulated genes (e.g. those involved in proteostasis) in untreated LCA-1 organoids had an even higher expression upon drug treatment. Similarly, the expression of genes upregulated in untreated samples was lowered even more than the controls by reserpine treatment. Curiously, treatment of LCA-1 organoids with 10 µM or 20 µM reserpine did not yield sufficient DE genes for further analyses (data not shown).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Transcriptomic upregulation of proteasomal components induced by reserpine in patient retinal organoids.</title><p>(<bold>A</bold>) Principal component analysis (PCA) diagram of patient and control organoids shows altered retinal transcriptomes after reserpine treatment. (<bold>B</bold>) Drug-induced genes in patient organoids displayed specific trends compared to control organoids. (<bold>C</bold>) Volcano plot summarizes reserpine-induced differential gene expression changes in LCA-1 organoids. (<bold>D</bold>) ClueGO analysis of KEGG pathway enrichment showed overexpressed genes mapping to protein homeostasis, metabolism, and cellular signaling processes. The red rectangle highlights the ‘Proteasome’ pathway. (<bold>E</bold>) GSEA plot showing enrichment and significance of Proteostasis Network. (<bold>F</bold>) Histogram of the log fold change of Proteostasis Network genes upon reserpine treatment. (<bold>G</bold>) Proteasomal subunits responded strongly to reserpine treatment. (<bold>H</bold>) SQSTM1 (p62) and (<bold>I</bold>) NFE2L2 (NRF2), two key regulators of protein homeostasis, showed increased expression after reserpine treatment.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Differentially expressed genes in reserpine-treated retinal organoids.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83205-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Reserpine treatment alters expression of retinal pathway genes.</title><p>(<bold>A</bold>) Timeline of treatment and sample harvest. (<bold>B</bold>) Different retinal cell types appeared to respond uniquely to reserpine. (<bold>C</bold>) Phototransduction genes were globally downregulated except for specific genes like OPN3. (<bold>D</bold>) Genes associated with photoreceptor cilia showed mixed trends. (<bold>E</bold>) Functional clustering of differentially expressed genes shows activity in cell survival pathways. (<bold>F</bold>) <italic>TP53</italic> gene expression change with reserpine treatment. (<bold>G</bold>) Heatmap of p53 signaling pathway (combination of KEGG, Reactome, and Hallmark genes). (<bold>H</bold>) Transcriptional response of <italic>TSC1</italic> and <italic>TSC2</italic> genes show reduced expression after reserpine treatment. (<bold>I</bold>) Expression of mTOR pathway genes upon reserpine treatment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig4-figsupp1-v2.tif"/></fig></fig-group><p>We first analyzed the expression level of genes specific to different retinal cell types and those involved in phototransduction and photoreceptor outer segment structure/function. Reserpine treatment modulated the expression of marker genes for inner retina cell types, including Müller glia (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>); however, surprisingly, several rod and cone photoreceptor genes (e.g. <italic>OPN1SW</italic> and <italic>GRK7</italic>) showed lower expression (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>), with <italic>CEP290</italic>-associated cilia genes (<xref ref-type="bibr" rid="bib80">Rachel et al., 2012</xref>) exhibiting varying changes in expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>).</p><p>As reserpine did not seem to directly regulate the expression of key components involved in disease pathology, we mapped the overexpressed genes to KEGG pathways and created an enrichment network. Using a cutoff of three genes with minimum overlap and 5% impact, the annotation network was plotted to visualize leading ontology terms (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Clusters of metabolism, proteostasis, and immune pathways, together with cell survival-related processes, were apparent in the network. To better understand functional connectivity among DE genes, we performed a Random-walktrap analysis on their protein-protein interactions network to identify co-functioning over- and under- expressing genes and identified three prominent modules (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Functional module 1 was comprised of extracellular matrix (ECM) and ECM-receptor interaction, and advanced glycation end products (AGE)-Receptor for AGE (RAGE) signaling pathway genes. Müller glia-specific genes <italic>MMPL14</italic>, <italic>TIMP1</italic>, and <italic>VIM</italic> were included in this module. Functional module 2 consisted of inflammation- and proteasome-related genes, which are consistent with the reported role of reserpine as an autophagy modulator (<xref ref-type="bibr" rid="bib61">Lee et al., 2015</xref>). Notably, functional module 3 contained critical cell survival factors such as p53 signaling and cellular senescence-associated genes. We further investigated the trend of the p53 network to characterize its role in response to drug treatment. Expression of <italic>TP53</italic>, the gene coding p53, was found to increase and match the level of control organoids (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>). In addition, a widespread modulation of each component of the p53 signaling network was evident upon reserpine treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). Downstream targets of p53, including metabolic modulator TSC and mTOR complex genes, responded to reserpine and returned to the level of control organoids (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>). Two components of the mTORC1 signaling pathway, <italic>RHEB,</italic> and <italic>LAMTOR1</italic>, were over-expressed after the drug treatment (<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). As mTORC1 is a key regulator of cellular metabolism, we observed significantly elevated expression of <italic>SLC2A1</italic> (GLUT) which is the primary glucose transporter in neurons (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1I</xref>).</p><p>Given the reported actions of reserpine in neuronal cells (<xref ref-type="bibr" rid="bib61">Lee et al., 2015</xref>), consistent with activation of mTORC1 activation (<xref ref-type="bibr" rid="bib51">Kim and Guan, 2015</xref>) and ‘proteasome’ subunit-encoding genes (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), we performed a focused gene set enrichment analysis to test the impact on the proteostasis network (PN). A PN geneset was manually curated from KEGG and Reactome using keywords reviewed from previous publications (<xref ref-type="bibr" rid="bib47">Jayaraj et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Klaips et al., 2018</xref>). We detected a significant positive net enrichment of PN in patient organoids after reserpine treatment (NES = 1.37, adj. p-value = 1.6e−11; <xref ref-type="fig" rid="fig4">Figure 4E</xref>), as measured by log<sub>2</sub> fold change in expression of all PN genes (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). We also identified global overexpression of proteasomal subunits, some of which were notably induced with fold change &gt;2 (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). In concordance, expression of the key regulators of proteostasis and members of the p53 network, p62 (<italic>SQSTM1</italic>) and NRF2 (<italic>NFE2L2</italic>), were significantly augmented in reserpine-treated patient organoids (<xref ref-type="fig" rid="fig4">Figure 4H, I</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>).</p></sec><sec id="s2-5"><title>Restoration of proteostasis in patient photoreceptors</title><p>To experimentally examine the role of PN in the survival of <italic>LCA10</italic> photoreceptors, we supplemented organoid cultures with various autophagy inhibitors (MRT68921, Lys05, chloroquine, hydroxychloroquine, ROC-325) that target different steps of the autophagy pathway using the same timeline as reserpine treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, B</xref>). MRT68921 and Lys05 inhibit the initiation of autophagy (<xref ref-type="bibr" rid="bib38">Galluzzi et al., 2017</xref>) and were highly toxic even at one-fourth of the reported EC<sub>50</sub>. Hydroxychloroquine and a more specific and efficient small molecule autophagy inhibitor ROC-325 enhanced the number of RHO+ cells in patient organoids with more polarized localization of rhodopsin to the apical side (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Quantification of the fluorescence intensity of rhodopsin immunostaining demonstrated a consistent trend and hydroxychloroquine- and ROC-325-treated organoids had a significantly higher expression of rhodopsin (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Although statistically non-significant, chloroquine-treated organoids also showed a positive trend in rhodopsin expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), providing further evidence in support of the autophagy pathway as a target for designing therapies.</p><p>To further determine the role of autophagy, we evaluated the level of cargo receptor sequestosome 1 (SQTM1) or p62, which recognizes cellular components and helps in the formation of autophagosomes for proteolysis (<xref ref-type="bibr" rid="bib69">Mizushima, 2007</xref>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). We noted that LCA-1 patient organoids had a significantly lower level of p62 compared to the control, and reserpine treatment significantly elevated p62 levels by more than twofold (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), consistent with previous studies (<xref ref-type="bibr" rid="bib61">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Bresciani et al., 2018</xref>). Significantly higher levels of LC3-II in patient organoids also indicated accumulation of autophagosomes (defects in autophagy), and reserpine treatment revealed a trend of decreasing LC3-II levels (though not statistically significant) in patient organoids (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The comparable ratio of LC3-II/LC3-I indicated a similar rate of autophagosome formation between control and patient organoids, suggesting that increased LC3-II levels in patient organoids could be due to overexpression of autophagy pathway components. Consistent with the reported function of reserpine as an autophagy inhibitor, the treated patient organoids had a significantly lower LC3-II/LC3-I ratio, although we did not detect a significant difference between the control and patient organoids (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Proteostasis Network in patient organoid cultures in response to reserpine treatment.</title><p>(<bold>A</bold>) Schematic diagram of autophagy.(<bold>B</bold>) Immunoblot analyses and quantification of autophagy cargo adaptor p62 and autophagosome marker LC-II in control and patient organoids treated with reserpine (RSP). (<bold>C</bold>) Schematic diagram showing the proteome balance between ubiquitin-proteasome system (UPS) and autophagy is mediated through p62 as documented in the literature. (<bold>D</bold>) Immunoblot analysis of the 20S proteasome in control, DMSO-, and RSP-treated cultures. β-Actin was used as the loading control. (<bold>E</bold>) Proteasomal chymotrypsin-like activity in organoids. (<bold>F</bold>) Immunoblot analyses and quantification of key regulators of cilium assembly/disassembly in control, untreated, and RSP-treated patient organoids. The drug vehicle dimethylsulfoxide (DMSO) was added to the cultures in the untreated group at the same volume as the drugs. β-Actin was used as the loading control. The histograms summarize data in at least three batches of experiments, each of which had at least three retinal organoids per group. Each dot in the histogram shows data in one batch of experiment and are presented as mean ± standard deviation. One-way ANOVA followed by Tukey’s test. *p&lt;0.05; ***p&lt;0.005.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of p62.</title><p>RSP stands for reserpine. The size of the protein ladders, p62, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of LC3.</title><p>RSP stands for reserpine. The size of the protein ladders, LC3, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of β-Actin.</title><p>RSP stands for reserpine. The size of the protein ladders, β-Actin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of 20S proteosome and β-Actin.</title><p>RSP stands for reserpine. The size of the protein ladders, β-Actin, 20S proteosome, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of IFT88.</title><p>RSP stands for reserpine. The size of the protein ladders, IFT88, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of BBS6.</title><p>RSP stands for reserpine. The size of the protein ladders, BBS6, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data6-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata7"><label>Figure 5—source data 7.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of CEP164.</title><p>RSP stands for reserpine. The size of the protein ladders, CEP164, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data7-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata8"><label>Figure 5—source data 8.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of OFD1.</title><p>RSP stands for reserpine. The size of the protein ladders, OFD1, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data8-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata9"><label>Figure 5—source data 9.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of HDAC6.</title><p>RSP stands for reserpine. The size of the protein ladders, HDAC6, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data9-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata10"><label>Figure 5—source data 10.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of β-Actin.</title><p>RSP stands for reserpine. The size of the protein ladders, β-Actin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-data10-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Effect of autophagy inhibitors on patient organoids.</title><p>(<bold>A</bold>) Schematic diagram of autophagy with annotation of the drug effect of autophagy inhibitors. (<bold>B</bold>) Timeline of treatment and sample harvest. (<bold>C</bold>) Immunostaining of rhodopsin (green), S-opsin (red), and L/M-opsin (magenta) were used to evaluate the effect of chloroquine (<bold>Q</bold>), hydroxychloroquine (HQ), and ROC-325. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least two independent experiments, each of which had at least three organoids. (<bold>D</bold>) Quantification of fluorescence intensity of rhodopsin immunostaining. The shape of the Bee Swamp plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. The plot summarizes at least three independent experiments with at least one image quantified in each batch. Kruskal-Wallis test followed by Dunn’s test was used to compare the groups. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Bafilomycin A1 (BafA1) and Tubastatin A treatment on patient organoids.</title><p>(<bold>A</bold>) Timeline of BafA1 treatment. (<bold>B</bold>) Western blot and quantification of p62, LC3-II, and LC3-II/LC3-I ratio upon bafilomycin A1 (BafA1) treatment. The drug vehicle dimethylsulfoxide (DMSO) was added to the cultures in the untreated group at the same volume as the drug. β-Actin was used as the loading control. The histograms summarize data in at least three batches of experiments, each of which contained at least three retinal organoids per group. Each dot in the histogram shows data from one batch of experiment and are presented as the mean ± standard error. Unpaired <italic>t</italic>-test was performed to compare the untreated and treated groups. Unpaired <italic>t</italic>-test was used to compare the group. *p&lt;0.05. (<bold>C</bold>) Treatment timeline (left) and outcome of Tubastatin A treatment (right) as shown by immunostaining of rhodopsin (green) and S-opsin (red). In all images, nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least two independent experiments, each of which had at least three organoids. (<bold>D</bold>) Quantification of fluorescence intensity of rhodopsin immunostaining. The shape of the Bee Swamp plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. The plot summarizes at least three independent experiments, each of which contained at least with three organoids. At least one image is quantified in each batch. Unpaired <italic>t</italic>-test was used to compare the groups. *p&lt;0.05.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of LC3.</title><p>BafA1 stands for Bafilomycin A1. The size of the protein ladders, LC3, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s2sdata2"><label>Figure 5—figure supplement 2—source data 2.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of p62.</title><p>BafA1 stands for Bafilomycin A1. The size of the protein ladders, p62, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s2sdata3"><label>Figure 5—figure supplement 2—source data 3.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of β-Actin.</title><p>BafA1 stands for Bafilomycin A1. The size of the protein ladders, b-Actin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp2-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>LCA2-derived retinal organoids in response to reserpine (RSP) treatment.</title><p>(<bold>A</bold>) Western blot analyses of p62 and LC3 in dimethylsulfoxide (DMSO)- and RSP-treated LCA2 organoids. β-Actin was used as the loading control. (<bold>B</bold>) Quantification of immunoblots of p62 and LC3. The histograms summarize data in at least four batches of experiments, each of which had at least three retinal organoids per group. Each dot in the histogram shows data from one batch of experiment and are presented as the mean ± standard deviation. Mann-Whitney test was used to compare the groups. *p&lt;0.05. (<bold>C</bold>) Immunostaining of p62 in control, untreated, and treated patient retinal organoids. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. (<bold>D</bold>) Western blot analyses and quantification of ciliary marker OFD1 and HDAC6. Data in the histogram were summarized from data from three batches of differentiation, each of which has at least three organoids. Unpaired <italic>t</italic>-test was used to compare the groups. *p&lt;0.05.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of p62.</title><p>The size of the protein ladders, p62, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s3sdata2"><label>Figure 5—figure supplement 3—source data 2.</label><caption><title>The size of the protein ladders, p62, and relevant sample identity are labeled.</title><p>The size of the protein ladders, b-Actin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp3-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s3sdata3"><label>Figure 5—figure supplement 3—source data 3.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of OFD1.</title><p>The size of the protein ladders, OFD1, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp3-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s3sdata4"><label>Figure 5—figure supplement 3—source data 4.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of HDAC6.</title><p>The size of the protein ladders, HDAC6, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig5-figsupp3-data4-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig5-figsupp3-v2.tif"/></fig></fig-group><p>We then applied Bafilomycin A1 (BafA1), an inhibitor of autophagosome-lysosome fusion, to patient organoid cultures using the same timeline as reserpine treatment (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). A short 6-hr treatment with BafA1 did not alter the autophagy pathway in the control, as shown by comparable levels of p62 and LC3-II as well as LC3-II/LC3-I ratio (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>); however, patient organoids demonstrated a significant (up to 70%) increase of LC3-II and LC3-II/LC3-I ratio, suggesting an elevated autophagic flux in patient organoids, consistent with the rescue by reserpine treatment.</p><p>The ubiquitin-proteasome system (UPS) and autophagy are the two key pathways in proteostasis and are reported to interact through p62 (<xref ref-type="bibr" rid="bib59">Kumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib63">Liu et al., 2016</xref>; <xref ref-type="fig" rid="fig5">Figure 5C</xref>). We, therefore, investigated the response of UPS in patient organoids upon reserpine treatment. Untreated patient organoids revealed a high level of 20S proteasome, which could be barely detected in the control (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Nonetheless, both the control and untreated patient organoids showed comparable total catalytic activity and reserpine significantly elevated the proteasome activity (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These results suggest that an increase in 20S expression is likely a compensatory mechanism for compromised proteasome activity in patient organoids and that reserpine facilitates the clearance of accumulated cellular components and/or autophagosomes (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><p>We were intrigued by the reported links of autophagy to primary cilium biogenesis (<xref ref-type="bibr" rid="bib74">Pampliega et al., 2013</xref>; <xref ref-type="bibr" rid="bib99">Tang et al., 2013</xref>; <xref ref-type="bibr" rid="bib117">Yamamoto and Mizushima, 2021</xref>) and, therefore, looked at the expression of key regulators involved in ciliary transport, cilium assembly, and disassembly (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). We identified higher expression of OFD1 (oral-facial-digital syndrome 1), which when eliminated by autophagy is shown to promote ciliogenesis (<xref ref-type="bibr" rid="bib99">Tang et al., 2013</xref>), in patient organoids compared to the control even though autophagy activity was higher in the latter (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). This apparent ambiguity could be due to variations in autophagic adapter machinery for cargo identification. Nonetheless, reserpine treatment reduced OFD1 levels in patient organoids and should facilitate the initiation of cilia biogenesis. Another key regulator, histone deacetylase 6 (HDAC6), which deacetylates microtubules and destabilizes the primary cilium for disassembly (<xref ref-type="bibr" rid="bib94">Simões-Pires et al., 2013</xref>; <xref ref-type="bibr" rid="bib78">Pugacheva et al., 2007</xref>), was significantly elevated in patient organoids compared to the control. Dramatic reduction of HDAC6 by reserpine (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) would also have a favorable impact on cilia biogenesis. Consistent with this hypothesis, the addition of a selective HDAC6 inhibitor Tubastatin A to patient organoids improved rod photoreceptor development as shown by a higher number of RHO + cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C</xref>). Tubastatin A treatment enhanced the polarity of not only rhodopsin but also S-opsin, likely due to increased stability of intracellular microtubules and improved intracellular trafficking. Quantification of the fluorescence intensity of rhodopsin indicated a significant increase of rhodopsin expression in tubastatin A-treated organoids (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D</xref>), suggesting a favorable effect on rod photoreceptor development probably through the inhibition of HDAC6.</p><p>To validate the effect of reserpine, we assessed the autophagy machineries and relevant ciliary markers in a less responsive LCA-2 clone F upon reserpine treatment. Consistent with LCA-1, reserpine treatment significantly increased the p62 level but did not alter LC3-II/LC3-I ratio in LCA-2 organoids (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A, B</xref>). Although statistically non-significant, the level of autophagosome showed a decreasing trend in organoids treated with reserpine (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A, B</xref>). As retinal organoids contain abundant retinal cell types besides photoreceptors, we performed immunostaining of p62 on control, untreated, and treated LCA1 and LCA2 organoids. As shown in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C</xref>, p62 staining could barely be observed in both patient organoids compared to the control. Reserpine treatment dramatically increased p62 staining in both photoreceptors and other retinal cell types. We also quantified the level of OFD1 and HDAC6, the two ciliary regulators that mediated the favorable effect of reserpine on outer segment biogenesis (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3D</xref>). We observed a significant decrease of HDAC6 in LCA2 organoids upon reserpine treatment. Although statistically non-significant, a lower expression of OFD1 was shown in reserpine-treated LCA2 organoids. Therefore, the action mechanisms of reserpine are independent of the responsiveness of patient organoids.</p></sec><sec id="s2-6"><title>Maintenance of photoreceptor survival in <italic>rd16</italic> mice in vivo</title><p>We then performed intravitreal injection of 40 µM reserpine into <italic>rd16</italic> mouse eyes at postnatal day (P)4, and the retinas were harvested at P21 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Reserpine was able to maintain photoreceptor survival, with a significantly thicker outer nuclear layer (ONL) in both the central and peripheral retina (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). As a small molecule drug, reserpine is highly diffusive, and we observed the effect of the drug in the contralateral eyes of the treated mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Indeed, bilateral therapeutic effects have been reported following unilateral injection in clinical treatments (<xref ref-type="bibr" rid="bib67">Michalska-Małecka et al., 2016</xref>; <xref ref-type="bibr" rid="bib87">Rouvas et al., 2009</xref>; <xref ref-type="bibr" rid="bib11">Calvo et al., 2016</xref>; <xref ref-type="bibr" rid="bib125">Zlotcavitch et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Rotsos et al., 2014</xref>). Reserpine-treated <italic>rd16</italic> mice showed a trend of increase in scotopic a-wave and a significant increase in scotopic b-wave (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>), suggesting functional recovery of rod photoreceptors upon reserpine treatment. No statistically significant difference was found in photopic a-wave or b-wave (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Notably, no systemic toxicity was observed in the treated mice. Injection of reserpine into WT mice did not lead to structural or functional alterations (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A and B</xref>), suggesting reserpine to be a safe treatment option.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Neuroprotective effect of reserpine (RSP) in <italic>rd16</italic> mouse retina.</title><p>(<bold>A</bold>) Timeline of in vivo intravitreal injection for quantification of outer nuclear layer (ONL), morphology, and immunohistochemistry studies. The eyes used for subsequent analyses were highlighted by red rectangles. (<bold>B</bold>) Immunostaining of dimethylsulfoxide (DMSO)- and reserpine (RSP)-treated <italic>rd16</italic> retina (left) and quantification of the GFP+ outer nuclear layer (ONL) thickness (right). The shape of the bee swamp plot indicates the distribution of data points from four different litters, in which at least one mouse was assessed. Data points are shown in colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean. Unpaired <italic>t</italic>-test was used to compare the mean. *p&lt;0.05. (<bold>C</bold>) Timeline of in vivo intravitreal injection for electroretinography (ERG) studies. (<bold>D</bold>) Scotopic and photopic electroretinogram responses in DMSO- and RSP-treated <italic>rd16</italic> mice. The lower panel shows individual values of a- and b-wave amplitudes at 10 cd.s/m<sup>2</sup> (scotopic) or at 100 cd.s/m<sup>2</sup> (photopic). ERG was measured in both eyes of at least one mouse from five different litters in each group (12 DMSO-treated and 16 RSP-treated mice). Data were expressed as mean ± SEM, and the Mann-Whitney U test was used to compare DMSO- and RSP-treated groups. ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Individual values of a- and b-wave amplitudes (µV) of scotopic and photopic electroretinogram responses in DMSO- and RSP-treated <italic>rd16</italic> mice.</title><p>RSP stands for reserpine.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Evaluation of reserpine (RSP) injection on photoreceptor layer in <italic>rd16</italic> mouse retina.</title><p>Evaluation of the impact of reserpine on outer nuclear layer (ONL) thickness of the central and peripheral retina. Each dot in the bee swamp plot indicates the ONL thickness of one retina from one mouse. The shape of the plot indicates the distribution of data points, which are shown by colorful circles in the center. The black diamond indicates the mean, and the error bar reveals the standard error of the mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Evaluation of reserpine (RSP) injection on photoreceptor structure and function in the wild-type (WT) mouse retina.</title><p>(<bold>A</bold>) Immunostaining of rod phototransduction protein rhodopsin (Rho, green), Pde6β (red), rod cell marker Reep6 (green), and cone opsin Opn1sw (red). Nuclei were stained by 4',6-diamidino-2- phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three mice, each of which was from a different litter. (<bold>B</bold>) Scotopic and photopic electroretinogram responses in dimethylsulfoxide (DMSO)- and RSP-treated wild-type (WT) mice. The lower panel shows individual values of a- and b-wave amplitudes at 10 cd.s/m<sup>2</sup> (scotopic) or at 100 cd.s/m<sup>2</sup> (photopic). Electroretinography (ERG) was measured in both eyes of at least four mice from different litters in each group. Data were expressed as mean ± SEM, and the Mann-Whitney U test was used to compare DMSO- and RSP-treated groups. ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Individual values of a- and b-wave amplitudes (µV) of scotopic and photopic electroretinogram responses in DMSO- and RSP-treated WT mice.</title><p>RSP stands for reserpine.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig6-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Effect of reserpine (RSP)-injection on distinct cell types in <italic>rd16</italic> mouse retina.</title><p>Retinal structures and cell types are shown by (<bold>A</bold>) rod phototransduction protein Pde6β (red) and rhodopsin (Rho, magenta), (<bold>B</bold>) PKCα (red) for bipolar cells (red) and Calretinin (magenta) for amacrine cells, (<bold>C</bold>) Cralbp (red) and Sox9 (magenta) for Müller glia, and (<bold>D</bold>) Gfap (red) for cellular stress. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three mice, each of which was from a different litter. (<bold>E</bold>) Western blot analyses and quantification of Gfap. The histogram summarizes at least three retinas from three mice of different litters. One-way ANOVA followed by Tukey’s test was used to compare the groups. *p&lt;0.05; **p&lt;0.01.</p><p><supplementary-material id="fig6s3sdata1"><label>Figure 6—figure supplement 3—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of Gfap.</title><p>The size of the protein ladders, Gfap, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig6-figsupp3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6s3sdata2"><label>Figure 6—figure supplement 3—source data 2.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of g-Tubulin.</title><p>The size of the protein ladders, g-Tubulin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig6-figsupp3-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig6-figsupp3-v2.tif"/></fig></fig-group><p>Consistent with the effects observed on human retinal organoids, reserpine treatment increased p62 levels (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), dramatically reduced the 20S proteasome (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), and significantly enhanced the proteasome activity (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Further analyses confirmed an improvement in the structure of photoreceptor outer segments of the treated <italic>rd16</italic> retina. Reserpine partially restored outer segment axonemes that were largely missing in untreated mouse retina (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). In addition, substantial ciliary rootlets were conspicuous in the inner segment (shown by GFP) and extended into the ONL. Phototransduction proteins including rhodopsin and Pde6β were transported to the outer segment (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A</xref>). In addition, the treatment with 40 µM reserpine did not alter the morphology of other retinal cell types or structures including bipolar neurons, amacrine cells, and Müller glia (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3B and C</xref>). Notably, the retinal stress marker Gfap was significantly increased in untreated <italic>rd16</italic> retina as compared to the WT and was significantly reduced upon reserpine treatment (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3D and E</xref>), suggesting a favorable effect of reserpine to retinal homeostasis.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>Rd16</italic> mouse retina in response to reserpine (RSP) treatment.</title><p>(<bold>A</bold>) p62 level in dimethylsulfoxide (DMSO)- and RSP-treated photoreceptors shown by immunostaining. (<bold>B</bold>) Quantification of p62 puncta. At least three non-overlap regions were quantified in at least one mouse from at least two different litters. One-way ANOVA followed by Tukey’s test was used to compare different groups. *p&lt;0.05. (<bold>C</bold>) Western blot analysis of 20S proteasome in wild-type (WT), DMSO-, and RSP-treated retina of <italic>rd16</italic> mice. γ-Tubulin was used as the loading control. (<bold>D</bold>) Proteasomal chymotrypsin-like activity in <italic>rd16</italic> retina. Data in the histogram were summarized from at least three mice from different litters and are presented as mean ± standard deviation. One-way ANOVA followed by Tukey’s test was used to compare different groups. *p&lt;0.05. (<bold>E</bold>) Immunostaining of outer segment (OS) axoneme marker RP1 (magenta, left panel) and ciliary rootlet marker Rootletin (magenta, right panel). In (<bold>A</bold>) and (<bold>E</bold>), nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). Arrowheads indicate relevant staining. Images were representative of at least three mice from different litters.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of 20S proteosome.</title><p>WT and RSP stand for wild-type and reserpine respectively. The size of the protein ladders, 20 S proteosome, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig7-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Overlay of the bright field and chemiluminescence images indicating the signal of γ-Tubulin.</title><p>WT and RSP stand for wild-type and reserpine respectively. The size of the protein ladders, γ-Tubulin, and relevant sample identity are labeled.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83205-fig7-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig7-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Repurposing of existing drugs for new unrelated clinical modalities provides an excellent opportunity for alleviating patient sufferings in a timely and cost-effective manner (<xref ref-type="bibr" rid="bib5">Begley et al., 2021</xref>). HTS of approved small molecule drugs can be based on simple assays that target the modulation of a disease-related phenotype or molecule. The use of patient-derived iPSCs and their derivatives, including differentiated cell types in two-dimensional or organoids in three-dimensional cultures, have substantially enhanced the prospects of successful drug discovery (<xref ref-type="bibr" rid="bib96">Struzyna and Watt, 2021</xref>; <xref ref-type="bibr" rid="bib34">Engle and Puppala, 2013</xref>). Exciting screening platforms are now being applied to retinal cells and organoids for drug discovery (<xref ref-type="bibr" rid="bib113">Welsbie et al., 2017</xref>; <xref ref-type="bibr" rid="bib109">Vergara et al., 2017</xref>). We note the success of cross-species screening, in which the drug candidates identified using one species could be effective in another species (<xref ref-type="bibr" rid="bib122">Zhang et al., 2021a</xref>). Given the ‘orphan’ status of IRDs, extensive genetic and phenotypic heterogeneity, and predominantly early dysfunction/death of rods, we designed a simple assay using GFP-tagged rods from iPSCs of a mouse mutant that phenocopies <italic>LCA10</italic> and established an HTS platform to identify small-molecule drugs to maintain photoreceptor survival. As a two-dimensional primary or stem cell-derived cultures demonstrate a relatively lower variation and have generated promising candidates in screenings (<xref ref-type="bibr" rid="bib113">Welsbie et al., 2017</xref>; <xref ref-type="bibr" rid="bib55">Kost-Alimova et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Mills et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2016b</xref>), we dissociated mouse retinal organoids into single cells and performed HTS in two-dimensional cultures. The identified lead compound reserpine was subsequently verified to be effective on patient organoids and in mouse mutant retina in vivo, suggesting the feasibility of our approach for drug discovery.</p><p>To our knowledge, there is no other study testing reserpine in other retinal diseases. Reserpine was approved for the treatment of hypertension in 1955 and later for the treatment of schizophrenia (<ext-link ext-link-type="uri" xlink:href="https://www.pubchem.gov/">https://www.pubchem.gov/</ext-link>); however, many better-tolerated and more potent hypertensive medications have become available during the last few decades. Though potential side effects of inhibition of presynaptic vesicle formation and consequently depression have been described for reserpine treatment (<xref ref-type="bibr" rid="bib119">Yohn et al., 2017</xref>), we did not observe adverse consequences on ribbon synapses or presynaptic vesicles in treated organoids or retinal function in WT mouse retina in vivo (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>). Our results are consistent with a previous study demonstrating the little effect of reserpine on central sympathetic activity in cats (<xref ref-type="bibr" rid="bib46">Iggo and Vogt, 1960</xref>). Additionally, the doses of reserpine for the treatment of hypertension or schizophrenia in adults range from 8 mg/kg to 80 mg/kg for a 60 kg adult (<xref ref-type="bibr" rid="bib18">Cheung and Parmar, 2023</xref>), which is higher than the dose we used in mouse studies (9.6 mg/kg). Reserpine has also been intramuscular or intravenous injection at a dose of 1 mg/kg to assess the modulation of the outcome of intraocular pressure drug and allergic inflammation of the eye in rabbits (<xref ref-type="bibr" rid="bib72">Okada and Shimada, 1980</xref>; <xref ref-type="bibr" rid="bib26">Delamere and Williams, 1985</xref>). No adverse effects have been reported in both studies. Besides, local delivery by intravitreal injection or via eye drops should be sufficient for reserpine to elicit its effects in the retina due to the highly diffusive properties of small-molecule drugs. Thus, we suggest that reserpine could be a safe therapeutic approach for the treatment of <italic>LCA10</italic> and probably other retinal ciliopathies. Future studies will focus on toxicity evaluation as well as on identifying more potent and less toxic derivatives of reserpine to initial clinical trials.</p><p>Transcriptomic analyses have permitted us to interrogate potential mechanism(s) of reserpine action in patient organoids and implicated signaling pathways involved in immune response (e.g. primary immunodeficiency, complement, and coagulation cascade), cell survival, and cell death (e.g. p53 signaling pathway, cellular senescence, apoptosis), metabolism (e.g. glutathione metabolism, purine metabolism), and proteostasis. Indeed, these pathways have highly intricate relationships. The p53 protein acts as a sensor of stress conditions and can act both as a transcriptional activator or repressor to promote cell death and cell survival decisions (<xref ref-type="bibr" rid="bib58">Kruiswijk et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib116">Wylie et al., 2022</xref>). Gene profiles of treated patient organoids revealed a significant increase of <italic>TP53</italic> as well as its downstream targets including key cellular metabolic regulator TSC and mTOR complexes. More importantly, the expression level of genes involved in TSC and mTOR complexes returned to the level of control organoids, suggesting a positive impact of reserpine in restoring photoreceptor metabolism. As both TSC knockout and mTOR complex 1 activation are reported to maintain photoreceptor survival (<xref ref-type="bibr" rid="bib106">Venkatesh et al., 2015</xref>; <xref ref-type="bibr" rid="bib107">Venkatesh et al., 2016</xref>), the trends in our experimental system suggest a cell survival effect of the p53 pathway through the modulation of cell metabolism. In addition, the expression of several Müller glia-specific genes was altered by reserpine, with GFAP levels reduced in mouse retina in vivo (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3D and E</xref>). Müller glia is believed to play a major role in reactive gliosis and likely adapt their transcriptome to support photoreceptors in retinal degeneration (<xref ref-type="bibr" rid="bib101">Tomita et al., 2021</xref>; <xref ref-type="bibr" rid="bib73">Palko et al., 2022</xref>). Yet, we are unsure whether reserpine directly acts on Müller glia to augment photoreceptor survival, or its response is a consequence of improved microenvironment and reduced retinal stress. Notably, the primary cilium appears to have a role in Müller glia maturity and functions in primary cultures (<xref ref-type="bibr" rid="bib37">Ferraro et al., 2015</xref>). Whether and how Müller glia are affected in <italic>LCA10</italic> or other degenerative diseases and their role in photoreceptor survival are active areas of investigation.</p><p>CEP290 is localized at the connecting cilium of photoreceptors and serves as a protein complex hub to control the biogenesis and function of outer segments. Hypomorphic CEP290 in the mouse degenerative model <italic>rd16</italic> leads to malformed connecting cilia, compromised development of outer segments, and mislocalization of phototransduction machineries (<xref ref-type="bibr" rid="bib13">Chang et al., 2006</xref>; <xref ref-type="bibr" rid="bib81">Rachel et al., 2015</xref>). Comparable phenotypes are observed in <italic>LCA10</italic> patient-derived retinal organoids (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Parfitt et al., 2016</xref>). Ciliary defects lead to the accumulation of outer segment proteins (e.g. opsin) in the endoplasmic reticulum (ER) and subsequently induce the unfolded protein response (<xref ref-type="bibr" rid="bib85">Reiter and Leroux, 2017</xref>), which plays a crucial role in the regulation of autophagy, a key quality control mechanism for degradation and recycling of components in response to starvation, growth factor deprivation, ER stress, and pathogen infection (<xref ref-type="bibr" rid="bib44">He and Klionsky, 2009</xref>). Although autophagy is a protective surveillance mechanism, chronic protein stress, such as in the case of IRD and aging retina, may dysregulate the degradation machineries and subsequently lead to cell death due to disruption of cellular proteostasis (<xref ref-type="bibr" rid="bib112">Weinberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2019</xref>). Loss of proteostasis has been shown to attribute to the pathogenesis of retinal and macular degeneration including IRD and age-related macular degeneration (AMD) (<xref ref-type="bibr" rid="bib112">Weinberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Faber and Roepman, 2019</xref>; <xref ref-type="bibr" rid="bib100">Tolone et al., 2022</xref>). Cellular proteostasis is largely maintained by the autophagy-lysosome pathway and the ubiquitin-proteasome system (UPS). Multiple studies reveal that modulation of autophagy or UPS could be a promising therapeutic approach to maintain photoreceptor survival in IRD (<xref ref-type="bibr" rid="bib79">Qiu et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Sen et al., 2021</xref>; <xref ref-type="bibr" rid="bib118">Yao et al., 2018</xref>) and AMD (<xref ref-type="bibr" rid="bib123">Zhang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib110">Vessey et al., 2022</xref>). A favorable effect of autophagy inhibition has also been reported for retinal ganglion cell survival (<xref ref-type="bibr" rid="bib120">Zaninello et al., 2020</xref>). Interestingly, both proteasome inhibition and activation have been shown to be able to maintain photoreceptor survival and function in a mouse degenerative model P23H carrying misfolding of rhodopsin (<xref ref-type="bibr" rid="bib79">Qiu et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Sen et al., 2021</xref>). This suggests a more complicated regulatory mechanism in the restoration of proteostasis. We observed increased autophagic flux in <italic>LCA10</italic> patient organoids together with reduced p62 and accumulation of autophagosome (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>). Though it seems counterintuitive to reduce autophagic flux as the accumulated protein would aggravate disease pathology, we note that reserpine treatment facilitated the clearance of autophagosome at least partially through the activation of the UPS in both retinal organoids and in vivo mouse retina (<xref ref-type="fig" rid="fig5">Figure 5 B-E</xref> and <xref ref-type="fig" rid="fig7">Figure 7 A-D</xref>). Although no significant difference in 20 S proteasome activity was found in patient-derived organoids or <italic>rd16</italic> mouse retina as compared to the control/WT (<xref ref-type="fig" rid="fig5">Figures 5E</xref> and <xref ref-type="fig" rid="fig7">7D</xref>), a higher expression of 20 S proteasome was observed (<xref ref-type="fig" rid="fig5">Figures 5D</xref> and <xref ref-type="fig" rid="fig7">7C</xref>), suggesting a compromised proteosome activities in patient-derived organoids and <italic>rd16</italic> retina. The UPS and autophagy reciprocally regulate the activity of each other through the common cargo adaptor p62 (<xref ref-type="bibr" rid="bib59">Kumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib63">Liu et al., 2016</xref>). Consistent with a previous study (<xref ref-type="bibr" rid="bib61">Lee et al., 2015</xref>), reserpine increased the p62 level, which should facilitate the activation of UPS. Consistently, we observed clearance of accumulated autophagosome even though an autophagy inhibitor reserpine was applied (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Therefore, we propose that, instead of modulating a single pathway, the proteostasis network should be considered as a whole system in developing therapies (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Further studies are needed to dissect the proteostasis network and understand the mechanisms of recognition of targeted components for degradation.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Action mechanisms of reserpine in photoreceptor survival.</title><p><italic>CEP29</italic>0 mutations lead to defects in the outer segment biogenesis and consequently, ciliary vesicles carrying building blocks of the primary cilium and ciliary proteins are accumulated in patient photoreceptors, leading to the activation of autophagy to degrade unwanted materials. As an autophagy inhibitor, reserpine downregulates autophagy and increases the p62 level in photoreceptors. As p62 is a mediator and cargo adaptor of the ubiquitin-proteasome system and autophagy, upregulation of p62 not only activates the 20 S proteasome to facilitate the clearance of the accumulated autophagosome but also facilitates the degradation of histone deacetylase 6 (HDAC6), which deacetylates microtubules. Removal of HDAC6 in photoreceptors thus should improve the stability of intracellular microtubules and facilitate the transport of pre-ciliary vesicles to the mother centriole for outer segment biogenesis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83205-fig8-v2.tif"/></fig><p>Improved outer segment biogenesis is another prominent effect of reserpine in our study, which is consistent with a previous study showing reserpine induces rod outer segment elongation (<xref ref-type="bibr" rid="bib56">Kralj and Pipan, 1998</xref>). As a key signaling regulator, the primary cilium is essential for the activation of starvation-induced autophagy through modulation of the Hedgehog pathway and other components involved in autophagy, which can eliminate components in intraflagellar transport (<xref ref-type="bibr" rid="bib74">Pampliega et al., 2013</xref>) as well as remove OFD1 from distal appendages to initiate cilium biogenesis (<xref ref-type="bibr" rid="bib99">Tang et al., 2013</xref>). Thus, the outcome of the crosstalk between ciliogenesis and autophagy seems to largely depend on cell type and physiological context. Our observation of high OFD1 levels in patient organoids compared to the control, despite an elevated autophagic flux, suggests alternative mechanisms. HDAC6 has also been demonstrated to promote autophagosome maturation (<xref ref-type="bibr" rid="bib60">Lee et al., 2010</xref>; <xref ref-type="bibr" rid="bib14">Chang et al., 2021</xref>) as well as deacetylate microtubules to impede intracellular trafficking, which is a key driver of primary cilium disassembly. Higher expression of HDAC6 in patient organoids could explain both the failure of docking of pre-ciliary vesicles (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>) and elevated autophagic flux in patient photoreceptors. HDAC6 is shown to be a target of p62 for degradation, and an increase in p62 in photoreceptors can reduce HDAC6 leading to improved outer segment length (<xref ref-type="bibr" rid="bib102">Toulis et al., 2020</xref>). We suggest that reserpine-induced p62 levels can facilitate the degradation of HDAC6 and augment the intracellular transport of preciliary vesicles to the mother centriole for cilia biogenesis (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><p>In conclusion, we identified a repurposing small-molecule drug reserpine to maintain photoreceptor survival in retinal ciliopathies, specifically <italic>LCA10</italic>, and at least partially act by restoration of proteostasis in photoreceptors. Reserpine has been evaluated in a human context (using patient organoids) and mouse retina in vivo and thus holds promise in future clinical studies. As the loss of proteomic homeostasis is a major cause of multiple retinal degenerative diseases (<xref ref-type="bibr" rid="bib35">Faber and Roepman, 2019</xref>), reserpine and its derivatives have clinical potential for gene-agnostic therapies. Despite the identification of pathways associated with reserpine action, it is hard to dissect the function of each pathway as they are highly intertwined with each other. We realize that transcriptomic analysis to elucidate drug effect was performed with organoids of a single patient (LCA-1). In addition, the drug candidate we identified using mouse organoids is effective on patient organoids and mouse retina in vivo; however, certain pathogenetic pathways specific to humans might be missing in the drug target search by the current HTS strategy. A major future direction will be to evaluate the effect and safety of different dosages of reserpine on photoreceptor survival and function in multiple degenerative mouse models and using patient iPSC-derived retinal organoids of other ciliopathies in IRD.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p><italic>B6.Cg-Cep290rd16/Boc</italic> mice (Strain #: 012283; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:012283">IMSR_JAX:012283</ext-link>) were obtained from the Jackson Laboratory and crossed to <italic>Nrlp-eGFP</italic> mice (<xref ref-type="bibr" rid="bib1">Akimoto et al., 2006</xref>) to generate <italic>Nrlp-EGFP; Cep290<sup>rd16/rd16</sup></italic> mice (referred to as <italic>rd16</italic>). The absence of the <italic>rd8</italic> mutation in the colony was assessed by PCR. All animal procedures were approved by the Animal Care and Use committee of the National Eye Institutes (Animal study protocol NEI-650) and adhered to ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice were housed in an atmosphere controlled-environment (temperature: 22°C ± 2°C, humidity: 30–70%), under a 12 hr dark/12 hr light cycle, and supplied with food and water ad libitum. Food, water, and nesting material were changed weekly.</p></sec><sec id="s4-2"><title>Mouse and human pluripotent cell lines</title><p>The mouse <italic>Nrl</italic>-GFP WT and <italic>rd16</italic> iPSC lines were obtained by infection of the E14.5 <italic>Nrlp-eGFP</italic> and <italic>rd16</italic> mouse embryonic fibroblasts with Dox-inducible lentiviral vectors carrying <italic>Pou5f1</italic>, <italic>Sox2</italic>, <italic>Klf4</italic>, and <italic>Myc</italic> genes individually, as previously described (<xref ref-type="bibr" rid="bib15">Chen et al., 2016a</xref>; <xref ref-type="bibr" rid="bib70">Mookherjee et al., 2018</xref>). To obtain human iPSC lines, fibroblasts of the familial control, two clones of <italic>LCA10</italic> patient 1 (annotated as LCA-1 and LCA-1-clone C), and two clones of <italic>LCA10</italic> patient 2 (annotated as LCA-2 and LCA-2-clone D) were isolated from skin biopsies and reprogrammed using integration-free Sendai virus by the iPSC Core Facility at National Heart, Lung, and Blood Institute of the National Institutes of Health using the established protocol (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Beers et al., 2015</xref>). All mouse and human iPSC lines were karyotypically normal except the <italic>rd16</italic> line 2, which had one missing sex chromosome and thus, was not used for subsequent high-throughput screening and secondary validation assays (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). All cultures were tested for mycoplasma contamination by real-time PCR periodically.</p></sec><sec id="s4-3"><title>Maintenance of iPSC</title><p>The WT and <italic>rd16</italic> iPSC lines were maintained as previously described (<xref ref-type="bibr" rid="bib17">Chen et al., 2020</xref>). Briefly, the iPSC lines were maintained on feeder cells (Millipore) in a maintenance medium constituted by Knockout DMEM (ThermoFisher Scientific), 1 x MEM non-essential amino acids (NEAA) (Sigma), 1 x GlutaMAX (ThermoFisher Scientific), 1 x Penicillin-Streptomycin (PS) (ThermoFisher Scientific), 2000 U/ml leukemia inhibitory factor (LIF) (Millipore), and 15% ES cell-qualified fetal bovine serum (FBS) (ThermoFisher Scientific) at 37 °C, 5% CO<sub>2</sub>. Full media change was performed every day, with 55 µM β-Mercaptoethanol (2-ME) (ThermoFisher Scientific) freshly added. Cells were passaged using TrypLE Express (ThermoFisher Scientific) every two days.</p><p>Human iPSC lines were maintained in Essential 8 (E8) (ThermoFisher Scientific) on growth factor-reduced (GFR) Matrigel (Corning)-coated plates, with media fully changed daily. Cells were maintained at 37 °C, 5% O<sub>2</sub>, and 5% CO<sub>2</sub> and passaged at 60–80% confluency using the EDTA-based dissociation method (<xref ref-type="bibr" rid="bib50">Kelley et al., 2020</xref>).</p></sec><sec id="s4-4"><title>Differentiation of mouse and human retinal organoids</title><p>The modified HIPRO protocol was used to differentiate mouse iPSCs into retinal organoids (<xref ref-type="bibr" rid="bib15">Chen et al., 2016a</xref>; <xref ref-type="bibr" rid="bib17">Chen et al., 2020</xref>). At differentiation day (D)0, iPSCs were plated in low adhesion U-shaped 96-well plate (Wako) at a density of 3000–5000 cells per well in 100 µl retinal differentiation medium consisting of GMEM (ThermoFisher Scientific), 1 x NEAA, 1 x sodium pyruvate (Sigma) and 1.5%(v/v) knockout serum replacement (KSR) (ThermoFisher Scientific). At D1, 240 µl GFR-Matrigel (&gt;9.5 mg/ml) was diluted in 1.8 ml retinal differentiation medium and 20 µl diluent was aliquoted to each well of the 96-well plate. Retinal organoids from one 96-well plate were transferred to a 100 mm poly(2-hydroxyethyl methacrylate) (Sigma)-coated petri dish with 12 ml DMEM/F12 with GlutaMAX, 1x N2 supplement, and 1 x PS. The media were replaced by DMEM/F12 with GlutaMAX, 1 x PS, 1x N2 supplement, 1 mM taurine (Sigma), 500 nM 9-<italic>cis</italic> retinal (Sigma), and 100 ng/ml insulin-like growth factor 1 (IGF1) (ThermoFisher Scientific) at D10, and half-media change was performed every other day, with 55 µM 2-ME freshly added to the media. From D26 onward, 1 x NEAA, 1 x B27 supplement without Vitamin A (ThermoFisher Scientific), and 2%(v/v) FBS (ThermoFisher Scientific) were added to the culture. Half-media exchanges were performed every two days, with 55 µM 2-ME freshly added to the media. The cultures were incubated in 5% O<sub>2</sub> from D0 to D10 and in 20% O<sub>2</sub> from D10 onwards.</p><p>Human retinal organoid differentiation was performed as previously described (<xref ref-type="bibr" rid="bib83">Regent et al., 2020</xref>). Briefly, small clumps dissociated from iPSCs in one well of a six-well plate were resuspended in E8 medium supplemented with 10 µM Y-27632 (Tocris) and transferred into one 100 mm polyHEMA-coated petri dish for embryoid body (EB) formation. Media were supplied with neural induction media (NIM) (DMEM/F-12 (1:1)) (ThermoFisher Scientific), 1x N2 supplement, 1 x NEAA, 2 µg/ml heparin (Sigma) at D1 and D2 at a ratio of 3:1 and 1:1, respectively, and fully switched to NIM at D3. D7 EBs from one 100 mm petri dish were plated onto one GFR Matrigel-coated 60 mm dish and cultured in NIM, with media changed every 2–3 days. In the application requiring a large-scale production of retinal organoids, nicotinamide was added to the culture to reach a final concentration of 5 mM from D0 to D8 (<xref ref-type="bibr" rid="bib84">Regent et al., 2022</xref>). NIM was replaced by a 3:1 retinal induction medium (RIM) consisting of DMEM/F-12 supplemented with 1 x B27 without Vitamin A (ThermoFisher Scientific), 1% antibiotic-antimycotic solution (ThermoFisher Scientific), 1% GlutaMAX and 1 X NEAA at D16 and media change was performed every day until D28, on which the adherent cells were scraped off into small clumps (&lt;5 mm<sup>2</sup>) and split into two polyHEMA-coated 100 mm Petri dishes. The floating clumps were cultured in RIM supplemented with IGF1 (ThermoFisher Scientific) and 1 mM taurine (Sigma), with 55 µM 2-ME freshly added. From D38 onward, 10% fetal bovine serum was added to RIM supplemented with 20 ng/ml IGF-1, and 1 mM taurine. 1 µM 9-<italic>cis</italic> retinal was freshly supplemented to the cultures during media change from D63 to D91. From D91 till the end of differentiation, the concentration of 9-<italic>cis</italic> retinal was reduced to 0.5 µM and B27 without Vitamin A was replaced by N2. Once scraped, media were half changed every 2–3 days, with IGF1, taurine and 9-<italic>cis</italic> retinal freshly added to the media under dim light environment.</p></sec><sec id="s4-5"><title>Dissociation of mouse retinal organoids into single cells</title><p>Mouse retinal organoids were transferred into a 15 ml centrifuge tube using wide-bored transfer pipets and washed one time with 10 ml 1 x PBS (ThermoFisher Scientific). Prewarmed 1 ml 0.25% trypsin-EDTA was then added, and the tube was incubated at 37 °C for 10 min, with pipetting up and down for 10 times using P1000 pipetman at 5- and 10 min incubation. 10 ml retinal maturation media (DMEM/F12 with GlutaMAX, 1 x PS, 1x N2 supplement, 1 mM taurine, 500 nM 9-<italic>cis</italic> retinal, 1 x NEAA, 1 x B27 supplement without Vitamin A, 2%(v/v) FBS) was added to the tube. The tube was inverted several times before centrifugation at 200 g for 5 min. After removal of the supernatant, the cell pellet was resuspended in 1 ml retinal maturation media and filtered through a 40 µm cell strainer (BD Bioscience) before proceeding to subsequent analyses.</p></sec><sec id="s4-6"><title>Compound libraries</title><p>We used three different small molecule libraries for our screening efforts. The library of 1280 pharmacologically active compounds (LOPAC 1280) consists of a collection of small molecules with characterized biological activities commonly used to test and validate screening assays. The library of U.S. Food and Drug Administration (FDA)–2800 approved drugs was set up internally. The compounds were first dissolved in 100% DMSO to generate a stock concentration with a final concentration of 10 mM and subsequently diluted into seven concentrations and dispensed into 1536-well plates. The NCATS Mechanism Interrogation Plate (MIPE) 5.0 library contains a collection of 1912 compounds (approved for clinical trials).</p></sec><sec id="s4-7"><title>HTS assays</title><p>To optimize the assay for HTS, D25 WT, and <italic>rd16</italic> mouse retinal organoids were dissociated into single-cell suspension and plated in 5 µl retinal maturation medium II at a concentration of 3000, 4000, and 5000 cells per well in a 1536-well plate. After culturing in a 37 °C humidified incubator overnight, 5000 cells/well yielded an optimal plating density for both WT and <italic>rd16</italic> cultures and were selected for subsequent assays.</p><p>In the screening experiments for drug candidates, dissociated D25 WT-positive control and <italic>rd16</italic> mouse retinal organoids were filtered through a 35 µm cell strainer and dispensed into a 1536-well plate at a density of 5000 cells/well in 5 µl freshly prepared retinal maturation medium II using the Multidrop Combi Dispenser (Thermo Scientific). Cells were incubated in a 37 °C humidified incubator overnight for cell recovery and attachment to the plates. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates at a volume of 23 μl/well using an NX-TR pintool station (WAKO Scientific Solutions). Cells were treated with compounds for 48 hr, followed by the addition of 0.5 µl quencher, and GFP and DAPI signal intensities were quantified using the acumen Cellista (TTP, Labtech). The positive hits with a significant increase of GFP compared to the DMSO-treated cells were retested using dissociated retinal organoids from iPSCs without a GFP marker to remove autofluorescent false positives. The remaining drug candidates were further tested using a full 11-concentration setting (1:3 serial dilutions starting at 10 mM) in triplicate plates to prioritize the hits based on efficacy.</p><p>The primary and confirmatory screening data were analyzed using software developed internally at the NIH Chemical Genomics Center (NCGC) (<xref ref-type="bibr" rid="bib111">Wang et al., 2010</xref>). The plate data was processed as follows: We first ran quality control on the plate data by visual inspection, masking wells showing erroneous signals, e.g., localized groupings of wells exhibiting enhanced or inhibited signals. We then performed intra-plate normalization as follows:<disp-formula id="equ1"><label>[1]</label><mml:math id="m1"><mml:mi>E</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>100</mml:mn><mml:mi> </mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>C</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ2"><label>[2]</label><mml:math id="m2"><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mo>-</mml:mo><mml:mn>100</mml:mn><mml:mi> </mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>I</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>C</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>I</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>I</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mn>16</mml:mn><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ3"><label>[3]</label><mml:math id="m3"><mml:mi>F</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mn>100</mml:mn><mml:mi> </mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mi>C</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Where:</p><list list-type="simple"><list-item><p>WT = D25 WT retinal organoid cells with GFP marker = GFP+</p></list-item><list-item><p>RD16=D25 <italic>rd16</italic> retinal organoid cells with GFP marker = GFP−</p></list-item><list-item><p>Parental = Retinal organoids from iPSCs without GFP marker = GFP−</p></list-item><list-item><p>C = compound tested</p></list-item><list-item><p>GFP = GFP (channel 488) signal intensity</p></list-item><list-item><p>DAPI = DAPI (channel 405) signal intensity</p></list-item></list><p>When the data is normalized in this fashion, efficacy, toxicity, and fluorescence range from 0 to 100%. With this normalization completed, we compute dose-response curves as follows:<disp-formula id="equ4"><label>[4]</label><mml:math id="m4"><mml:mrow><mml:mi>A</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mn>50</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi>n</mml:mi></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Where <italic>C<sub>i</sub></italic> = the <italic>i’th</italic> concentration, <italic>A(C<sub>i</sub></italic>) = activity (efficacy, toxicity, or fluorescence) at concentration <italic>i</italic>, <italic>A<sub>0</sub></italic> = activity at zero concentration, <italic>A<sub>∞</sub></italic> = activity at infinite concentration, and <italic>EC<sub>50</sub></italic> = the concentration giving a response half-way between the fitted top (100%) and bottom (0) of the curve.</p><p>Compounds are desired that have high efficacy (<italic>EC<sub>50efficacy</sub></italic> = small, <italic>A<sub>∞, efficacy =</sub></italic> high), low toxicity, (<italic>EC<sub>50toxicity</sub></italic> = large), and low fluorescence (<italic>EC<sub>50fluorescence</sub></italic> = large).<disp-formula id="equ5"><label>[5]</label><mml:math id="m5"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></disp-formula><disp-formula id="equ6"><label>[6]</label><mml:math id="m6"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></disp-formula><disp-formula id="equ7"><label>[7]</label><mml:math id="m7"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:math></disp-formula></p><p>In addition, the dose-response curves for each measured quantity must be well behaved, i.e., (i) curves exhibit values near zero at low concentration, (ii) values increase with increasing concentration, (ii) curves show a well-defined inflection point at the <italic>EC<sub>50</sub></italic> concentration, and (iv) curves show a well-defined plateau at high concentration (<xref ref-type="bibr" rid="bib111">Wang et al., 2010</xref>).</p></sec><sec id="s4-8"><title>Immunoblot analysis</title><p>At least three organoids in each batch were homogenized in 100 μl of RIPA buffer (Sigma) supplemented with 1 x protease inhibitor (Roche) and 1 x phosphatase inhibitor (Roche). The lysate was agitated at 4 °C for half an hour, before centrifugation at 12,000 g for 10 min at 4 °C. The supernatant was either stored at –80 °C until use or quantified by Pierce bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific). Approximately 20 μg protein was diluted 4:1 in reducing 4 x Laemmli buffer (Biorad) and boiled for 10 min. The samples were separated at 150–180 V for 1 hr on 4–15% precast polyacrylamide gel (Biorad) and transferred to polyvinylidene fluoride (PVDF) membranes using a TransBlot Turbo Transfer System (Biorad). After blocking in 5% milk or 5% bovine serum albumin (BSA) for 1 hr at room temperature, the blots were incubated in antibody cocktails (Key Resources Table) overnight in 1% milk or BSA in 1 X TBS-T at 4 °C overnight with gentle agitation. Membranes were subsequently washed in 1 X TBS-T for three times, 10 min each, and incubated in 1 X TBS-T with horseradish peroxidase-conjugated secondary antibodies (1:5000) for 1 hr at room temperature, followed by another three 10 min wash. Before imaging, the membranes were exposed to SuperSignal West Pico enhanced chemiluminescence (ECL) solution (ThermoFisher Scientific) for 5 min, and chemiluminescence was captured using a Bio-Rad ChemiDoc touch (Bio-Rad).</p></sec><sec id="s4-9"><title>Chymotrypsin-like proteasome activity assay</title><p>The chymotrypsin-like protease activity associated with the proteasome complex in organoids or mouse retina was quantified using the Proteasome 20 S Activity Assay Kit (Sigma) following the manufacturer’s protocol. In short, at least three retinal organoids or one mouse retina were homogenized in 55 µl PBS mixed with 55 µl reconstituted Proteasome Assay Loading Solution and incubated on ice for 30 min. After centrifuging at 10,000 <italic>g</italic> for 10 min at 4 °C, 10 µl supernatant was taken for BCA assay to determine the protein amount and the remaining 100 µl was transferred to one well of black/clear 96-well plate for incubation at 37 °C. Protease activity of individual samples was measured by the fluorescence intensity (λex = 480–500 nm/λem = 520–530 nm) normalized to the protein amount.</p></sec><sec id="s4-10"><title>Transmission electron microscopy</title><p>Retinal organoids were processed for transmission electron microscopy (TEM) analysis as previously described (<xref ref-type="bibr" rid="bib93">Shimada et al., 2017</xref>). Briefly, the organoids were fixed in 4% formaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 (Tousimis) for 2 hr at room temperature, followed by three washes in cacodylate buffer before further fixation in osmium tetroxide (1% v/v in 0.1 M cacodylate buffer; Electron Microscopy Sciences) for 1 hr at room temperature. The organoids were then washed in the same buffer for three times, followed by one wash in acetate buffer (0.1 M, pH 4.2), and <italic>en-bloc</italic> staining in uranyl acetate (0.5% w/v; Electron Microscopy Sciences) in acetate buffer for 1 hr at room temperature. The samples were dehydrated in a series of ethanol solutions (35%, 50%, 75%, 95%, and 100%) and then by propylene oxide. The samples were subsequently infiltrated in a mixture of propylene oxide and epoxy resin (1:1, v/v) overnight, embedded in a flat mold with pure epoxy resin, and cured at 55 °C for 48 hr. 70–80 nm sections were made with an ultramicrotome (UC 7) and diamond knife (Diatome), attached on a 200-mesh copper grid, and counter-stained in the aqueous solution of uranyl acetate (0.5% w/v) and then lead citrate solutions. The thin sections were stabilized by carbon evaporation before the EM examination. The digital images were taken using a digital camera equipped with an electron microscope (H7650) (AMT).</p></sec><sec id="s4-11"><title>Flow cytometry</title><p>After dissociating retinal organoids, the cells were resuspended in DPBS (ThermoFisher Scientific) containing 1 mM EDTA (Millipore) and filtered through a 40 μm cell strainer. 4',6-diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific) was added to the samples before being analyzed by FACSAriaII (BD Bioscience). Cell viability was evaluated by integrity (gated by DAPI), size (gated by forward scatter, FSC), and granularity (gated by side scatter, SSC). WT retinal organoids without a GFP marker on the same differentiation day were used to set the gating for GFP + cells.</p></sec><sec id="s4-12"><title>RNA extraction and library preparation</title><p>Total RNA was purified from homogenized retinal organoids using TriPure isolation reagent (Roche). Quality of isolated RNAs was assessed using Bioanalyzer RNA 6000 nano assays (Agilent) and high-quality total RNA (RNA integrity number ≥7.5) was used for the construction of the mRNA sequencing library. 100 ng total RNA was used to construct the strand-specific libraries using TruSeq RNA Sample Prep Kit-v2 (Illumina).</p></sec><sec id="s4-13"><title>RNA-seq data analysis</title><p>RNA sequencing was performed as described (<xref ref-type="bibr" rid="bib52">Kim et al., 2016</xref>). Paired-end 125 bp reads were generated using Illumina sequencing. Reads were quality checked and mapped to the reference transcriptome using Kallisto. Alignments were imported into R using tximport for downstream analyses. The edgeR and limma pipeline were employed for differential expression analysis, while pathway annotation was performed using ClueGO (<xref ref-type="bibr" rid="bib8">Bindea et al., 2009</xref>). Protein interaction data were obtained from STRING (v11.5) with evidence cut off of 700, via the R package STRINGdb (<xref ref-type="bibr" rid="bib97">Szklarczyk et al., 2021</xref>). Network analysis was performed using the <italic>igraph</italic> package [<ext-link ext-link-type="uri" xlink:href="https://igraph.org/">https://igraph.org/</ext-link>] and genes were mapped to pathways using gProfileR (<xref ref-type="bibr" rid="bib82">Raudvere et al., 2019</xref>). Proteostasis network genes were manually collected by pooling KEGG and Reactome pathways with keywords from <xref ref-type="bibr" rid="bib47">Jayaraj et al., 2020</xref> and (<xref ref-type="bibr" rid="bib54">Klaips et al., 2018</xref>), and the proteosome map was adapted from KEGG (hsa03050). Gene set enrichment analysis was done using the R package fgsea. All other plotting and analyses, unless otherwise mentioned, were performed using tidyverse and base R packages.</p></sec><sec id="s4-14"><title>Immunohistochemistry</title><p>Mouse and human organoids were fixed in 4% PFA (Electron Microscopy Sciences) for 1 hr at room temperature, washed one time, and cryoprotected in 15% sucrose for at least 2 hr at room temperature, followed by 30% sucrose at 4 °C overnight. The next day, organoids were embedded in Shandon M-1 Embedding Matrix (ThermoFisher Scientific). The blocks were sectioned at 10 μm thickness and incubated at room temperature for at least 1 hr, before immunostaining or storage at −80 °C. After incubating in blocking solution (5% donkey serum in PBS) for 1 hr at room temperature, the sections were supplied with diluted primary antibodies (Key Resources Table) at 4 °C overnight. After three 10 min washes in PBS, Species-specific secondary antibodies conjugated with Alexa Fluor 488, 568, or 637, together with DAPI, were diluted in blocking solution (1:500; ThermoFisher Scientific) and incubated with the sections for 1 hr at room temperature. After washing in PBS for three times, 10 min each, the sections were mounted for imaging.</p><p>For mouse retinal sections, <italic>rd16</italic> mice of both sexes were injected at postnatal (P) day 4 and recovered at P21 after euthanasia using a CO<sub>2</sub> atmosphere. Eyes were enucleated before being pierced in the center of the cornea using a 26-gauge needle. Eyecups were then incubated for 15 min in 4% paraformaldehyde (PFA). The cornea and lens were then dissected, and the eyecups were placed in 4% PFA for 15 min at room temperature (RT) before proceeding to cryoprotection in 20 and 30% sucrose-PBS at 4 °C for 1 hr and overnight, respectively. Eyecups were then quickly frozen in Shandon M-1 Embedding Matrix (Thermo Fisher Scientific) and cut at 12 μm. Retinal sections were washed twice in PBS and then blocked in PBS containing 5% Donkey serum and 0.3% Triton X-100 (PBST) for 1 hr at room temperature. Slides were incubated overnight at 4 °C with the primary antibody diluted in PBST at an appropriate concentration (see Key Resources Table). Sections were then washed three times with PBS and incubated with a secondary antibody and 1 μg/ml 4,6-diamidino-2-phenylindole (DAPI) for 1 hr at room temperature. After three washes in PBS, the sections were mounted in Fluoromount-G (SouthernBiotech).</p></sec><sec id="s4-15"><title>Image acquisition and analysis</title><p>Bright field images were taken using an EVOS XL Core Cell Imaging System (ThermoFisher). Fluorescence images were acquired with LSM-880 confocal microscope (Zeiss) with Zen software. FIJI and Photoshop CC 2019 software was used for image export, analyzing, and processing. Rhodopsin and S-opsin fluorescent intensity of organoid sections were quantified with FIJI using the maximum intensity projections of z-stack images. Multi-channel RGB (red, green, blue) images were separated into 8-bit grayscale images, and regions of interest were identified by applying the “Moment” threshold algorithm of FIJI. The same threshold algorithm was used for all images. Area, raw, and integrated fluorescence intensity in each image were then quantified with Fiji and plotted using RStudio version 1.1.463.</p></sec><sec id="s4-16"><title>Intravitreal injection</title><p>Animal experiments were conducted in the animal facility at the National Eye Institute, the National Institutes of Health. The facility approved the animal care and experimental procedures used in this study (NEI-ASP650).</p><p>For evaluating the effect of reserpine, we performed two sets of experiments and examined mouse retinal function by electroretinography (ERG) and structure by histology and/or immunohistochemistry. In the first set, the mice were injected with reserpine at P4 and harvested at P21. In the other set, the mice were given two injections of the drug at P7 and P14, and the ERG was recorded at P24 before harvesting the retina for structural analysis. For intravitreal injections at P4, pups of either sex of <italic>Nrl</italic>-GFP <italic>rd16</italic> mice were anesthetized on ice and their eyelids were opened using a 30-gauge needle to gently expose the eye. Ketoprofen (0.5 µl of 1 mg/ml in PBS) was administered for analgesia. DMSO or reserpine (0.5 µl) was blindly injected using a glass micropipette (World Precision Instruments) produced by a Flaming-Brown micropipette puller (Sutter Instruments) and connected to an Eppendorf Femtojet air compressor (Eppendorf). For intravitreal drug injections at P7 and P14, mouse pups were anesthetized by intraperitoneal injection of ketamine (50 mg/kg body weight) and xylazine (5 mg/kg body weight). DMSO or reserpine (0.5–1 µl) was intravitreally injected using a Hamilton syringe with a 34-guage needle. Mice with eye/lens damage following the injection were excluded from further analyses.</p></sec><sec id="s4-17"><title>ERG recordings</title><p>ERG responses were recorded as previously published (<xref ref-type="bibr" rid="bib43">Hargrove-Grimes et al., 2020</xref>). Briefly, after an overnight dark adaptation, mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Eyes were dilated by topical administration of tropicamide (1% wt/vol, Alcon) and phenylephrine (2.5% wt/vol, Alcon), and the body temperature was maintained at 37 °C by a heating pad. After placing the reference electrode in the mouth and applying hypromellose ophthalmic demulcent solution (2.5% wt/vol, Gonak; Akorn) to each eye, gold wire loop electrodes were placed on the center of each cornea and ERG responses were recorded with an Espion E2 Visual Electrophysiology System (Diagnosys). Scotopic responses were recorded at increasing light intensities from 0.0001 to 10 cd·s/m<sup>2</sup> with inter-stimulus intervals ranging from 5 s to 60 s depending on stimulus intensity. After a light adaptation for 2 min, photopic responses were recorded at increasing light intensities from 0.3 to 100 cd·s/m<sup>2</sup> under a background light saturating rod function. The a-wave amplitudes were measured from the baseline to the negative trough and the b-wave amplitudes were measured from the a-wave trough to the wave peak. Mice with eye/lens damage following the injection were excluded from further analyses.</p></sec><sec id="s4-18"><title>Statistics</title><p>Based on the initial data, the sample size of animals used in each group was determined by an unpaired <italic>t</italic>-test to be less than six mice in each group (<ext-link ext-link-type="uri" xlink:href="http://www.biomath.info/">http://www.biomath.info/</ext-link>). For experiments involvng mouse or human retinal organoids, at least four independent experiments, each of which had at least three organoids, were performed unless specified. For animal studies, at least two retinas from one mouse of at least four different litters were evaluated. All data were expressed as mean ± standard deviation (SD) unless specified. An unpaired <italic>t</italic>-test was used to compare the mean between the two groups. For the comparison of three or more groups, one-way AVOVA was performed. Results with a <italic>&lt;</italic>i&gt;p-value &lt;0.05 were considered statistically significant.</p></sec><sec id="s4-19"><title>Material availability statement</title><p>All materials including the pluripotent stem cell lines and animals are available upon request. A Material Transfer Agreement complying with the guidelines of the National Institutes of Health has to be established before shipment.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Listed as inventor on a patent application related to the small molecules in this study by National Institutes of Health (PCT/US2021/040157)</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Software, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were approved by the Animal Care and Use committee of the National Eye Institutes (Animal study protocol NEI-650) and adhered to ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83205-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. RNA-seq data are available through GEO accession #206959.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Swaroop</surname><given-names>M</given-names></name><name><surname>Papal</surname><given-names>S</given-names></name><name><surname>Mondal</surname><given-names>AK</given-names></name><name><surname>Tawa</surname><given-names>G</given-names></name><name><surname>Regent</surname><given-names>F</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>de Val</surname><given-names>N</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Photoreceptor survival in CEP290-retinopathy by Reserpine involves modulation of proteostasis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE206959">GSE206959</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Tiansen Li, Linn Gieser, Matthew Brooks, Ryan A Kelley and Trupti Shetty (National Eye Institute), and Wenwei Huang (National Center for Advancing Translational Sciences) for technical support and insightful discussions. We are grateful to Rafael Villasmil, Julie Laux, Jessica Albrecht, and Jacqueline Minehart (Flow Cytometry Core Facility of the National Eye Institute), Lijin Dong, Pinghu Liu, and Jingqi Lei (Genetic Engineering Core Facility of the National Eye Institute), Jizhong Zou and Jeanette Beers (iPSC Core Facility at National Heart, Lung, and Blood Institute), Sandra Burkett (Molecular Cytogenetic Core Facility at National Cancer Institute), and Alan Hoofring and Ethan Tyler (Division of Medical Arts at National Institutes of Health) for assistance in various aspects of research. These studies were supported by the National Eye Institute Intramural Research Program (ZIAEY000450 and ZIAEY000546) and National Center for Advancing Translational Sciences Intramural Research Program (ZIATR000018-06) and utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health. We wish to dedicate this manuscript to the memory of Dr. Samuel G Jacobson, a dedicated clinician scientist, who unfortunately passed away during the preparation of the revised manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Brzezinski</surname><given-names>JA</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name><name><surname>Filippova</surname><given-names>E</given-names></name><name><surname>Oh</surname><given-names>ECT</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Linares</surname><given-names>J-L</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Zareparsi</surname><given-names>S</given-names></name><name><surname>Mears</surname><given-names>AJ</given-names></name><name><surname>Hero</surname><given-names>A</given-names></name><name><surname>Glaser</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting of GFP to newborn rods by NRL promoter and temporal expression profiling of flow-sorted photoreceptors</article-title><source>PNAS</source><volume>103</volume><fpage>3890</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508214103</pub-id><pub-id pub-id-type="pmid">16505381</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>SG</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Olsen</surname><given-names>AL</given-names></name><name><surname>Pearl</surname><given-names>D</given-names></name><name><surname>Vander Kamp</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1956">1956</year><article-title>The effects of reserpine on schizophrenic patients</article-title><source>A.M.A. Archives of Neurology and Psychiatry</source><volume>76</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1001/archneurpsyc.1956.02330260084008</pub-id><pub-id pub-id-type="pmid">13354039</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbelanne</surname><given-names>M</given-names></name><name><surname>Hossain</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>DP</given-names></name><name><surname>Peränen</surname><given-names>J</given-names></name><name><surname>Tsang</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nephrocystin proteins NPHP5 and CEP290 regulate BBSome integrity, ciliary trafficking and cargo delivery</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>2185</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu738</pub-id><pub-id pub-id-type="pmid">25552655</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beers</surname><given-names>J</given-names></name><name><surname>Linask</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>JA</given-names></name><name><surname>Siniscalchi</surname><given-names>LI</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>11319</elocation-id><pub-id pub-id-type="doi">10.1038/srep11319</pub-id><pub-id pub-id-type="pmid">26066579</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begley</surname><given-names>CG</given-names></name><name><surname>Ashton</surname><given-names>M</given-names></name><name><surname>Baell</surname><given-names>J</given-names></name><name><surname>Bettess</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name><name><surname>Carter</surname><given-names>B</given-names></name><name><surname>Charman</surname><given-names>WN</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Frazer</surname><given-names>I</given-names></name><name><surname>Gautam</surname><given-names>A</given-names></name><name><surname>Jennings</surname><given-names>MP</given-names></name><name><surname>Kearney</surname><given-names>P</given-names></name><name><surname>Keeffe</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>AF</given-names></name><name><surname>McGuckin</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name><name><surname>Rayner</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>B</given-names></name><name><surname>Rush</surname><given-names>JS</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Drug repurposing: misconceptions, challenges, and opportunities for academic researchers</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabd5524</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abd5524</pub-id><pub-id pub-id-type="pmid">34550729</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>CM</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Berlinicke</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human organoids for the study of retinal development and disease</article-title><source>Annual Review of Vision Science</source><volume>6</volume><fpage>91</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1146/annurev-vision-121219-081855</pub-id><pub-id pub-id-type="pmid">32936736</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>AI</given-names></name><name><surname>Stout</surname><given-names>KA</given-names></name><name><surname>Miller</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The vesicular monoamine transporter 2: an underexplored pharmacological target</article-title><source>Neurochemistry International</source><volume>73</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2013.12.003</pub-id><pub-id pub-id-type="pmid">24398404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>W-H</given-names></name><name><surname>Pagès</surname><given-names>F</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id><pub-id pub-id-type="pmid">19237447</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresciani</surname><given-names>A</given-names></name><name><surname>Spiezia</surname><given-names>MC</given-names></name><name><surname>Boggio</surname><given-names>R</given-names></name><name><surname>Cariulo</surname><given-names>C</given-names></name><name><surname>Nordheim</surname><given-names>A</given-names></name><name><surname>Altobelli</surname><given-names>R</given-names></name><name><surname>Kuhlbrodt</surname><given-names>K</given-names></name><name><surname>Dominguez</surname><given-names>C</given-names></name><name><surname>Munoz-Sanjuan</surname><given-names>I</given-names></name><name><surname>Wityak</surname><given-names>J</given-names></name><name><surname>Fodale</surname><given-names>V</given-names></name><name><surname>Marchionini</surname><given-names>DM</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Quantifying autophagy using novel LC3B and p62 TR-FRET assays</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0194423</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0194423</pub-id><pub-id pub-id-type="pmid">29554128</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnight</surname><given-names>ER</given-names></name><name><surname>Wiley</surname><given-names>LA</given-names></name><name><surname>Drack</surname><given-names>AV</given-names></name><name><surname>Braun</surname><given-names>TA</given-names></name><name><surname>Anfinson</surname><given-names>KR</given-names></name><name><surname>Kaalberg</surname><given-names>EE</given-names></name><name><surname>Halder</surname><given-names>JA</given-names></name><name><surname>Affatigato</surname><given-names>LM</given-names></name><name><surname>Mullins</surname><given-names>RF</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Tucker</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cep290 gene transfer rescues Leber congenital amaurosis cellular phenotype</article-title><source>Gene Therapy</source><volume>21</volume><fpage>662</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/gt.2014.39</pub-id><pub-id pub-id-type="pmid">24807808</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>CM</given-names></name><name><surname>Sridhar</surname><given-names>J</given-names></name><name><surname>Shahlaee</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reduction of diabetic macular edema in the untreated fellow eye following intravitreal injection of aflibercept</article-title><source>Ophthalmic Surgery, Lasers &amp; Imaging Retina</source><volume>47</volume><fpage>474</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.3928/23258160-20160419-12</pub-id><pub-id pub-id-type="pmid">27183553</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capowski</surname><given-names>EE</given-names></name><name><surname>Samimi</surname><given-names>K</given-names></name><name><surname>Mayerl</surname><given-names>SJ</given-names></name><name><surname>Phillips</surname><given-names>MJ</given-names></name><name><surname>Pinilla</surname><given-names>I</given-names></name><name><surname>Howden</surname><given-names>SE</given-names></name><name><surname>Saha</surname><given-names>J</given-names></name><name><surname>Jansen</surname><given-names>AD</given-names></name><name><surname>Edwards</surname><given-names>KL</given-names></name><name><surname>Jager</surname><given-names>LD</given-names></name><name><surname>Barlow</surname><given-names>K</given-names></name><name><surname>Valiauga</surname><given-names>R</given-names></name><name><surname>Erlichman</surname><given-names>Z</given-names></name><name><surname>Hagstrom</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>D</given-names></name><name><surname>Sluch</surname><given-names>VM</given-names></name><name><surname>Chamling</surname><given-names>X</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Skala</surname><given-names>MC</given-names></name><name><surname>Gamm</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines</article-title><source>Development</source><volume>146</volume><elocation-id>dev171686</elocation-id><pub-id pub-id-type="doi">10.1242/dev.171686</pub-id><pub-id pub-id-type="pmid">30567931</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name><name><surname>Hawes</surname><given-names>N</given-names></name><name><surname>Jimeno</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Lillo</surname><given-names>C</given-names></name><name><surname>Parapuram</surname><given-names>SK</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Hurd</surname><given-names>RE</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Otto</surname><given-names>EA</given-names></name><name><surname>Attanasio</surname><given-names>M</given-names></name><name><surname>O’Toole</surname><given-names>JF</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Shou</surname><given-names>C</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Williams</surname><given-names>DS</given-names></name><name><surname>Heckenlively</surname><given-names>JR</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>In-Frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>1847</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl107</pub-id><pub-id pub-id-type="pmid">16632484</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of HDAC6 in autophagy and NLRP3 inflammasome</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>763831</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.763831</pub-id><pub-id pub-id-type="pmid">34777380</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Kaya</surname><given-names>KD</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Three-Dimensional retinal organoids from mouse pluripotent stem cells mimic in vivo development with enhanced stratification and rod photoreceptor differentiation</article-title><source>Molecular Vision</source><volume>22</volume><fpage>1077</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">27667917</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Palczewska</surname><given-names>G</given-names></name><name><surname>Masuho</surname><given-names>I</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Brooks</surname><given-names>MJ</given-names></name><name><surname>Kiser</surname><given-names>PD</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name><name><surname>Martemyanov</surname><given-names>KA</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Palczewski</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Synergistically acting agonists and antagonists of G protein-coupled receptors prevent photoreceptor cell degeneration</article-title><source>Science Signaling</source><volume>9</volume><elocation-id>ra74</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aag0245</pub-id><pub-id pub-id-type="pmid">27460988</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Kelley</surname><given-names>RA</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIPRO: a high-efficiency, hypoxia-induced protocol for generation of photoreceptors in retinal organoids from mouse pluripotent stem cells</article-title><source>STAR Protocols</source><volume>1</volume><elocation-id>100018</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2020.100018</pub-id><pub-id pub-id-type="pmid">32754720</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>M</given-names></name><name><surname>Parmar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><source>Reserpine</source><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cideciyan</surname><given-names>AV</given-names></name><name><surname>Aleman</surname><given-names>TS</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name><name><surname>Sumaroka</surname><given-names>A</given-names></name><name><surname>Aguirre</surname><given-names>GK</given-names></name><name><surname>Schwartz</surname><given-names>SB</given-names></name><name><surname>Windsor</surname><given-names>EAM</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Centrosomal-ciliary gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis</article-title><source>Human Mutation</source><volume>28</volume><fpage>1074</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1002/humu.20565</pub-id><pub-id pub-id-type="pmid">17554762</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cideciyan</surname><given-names>AV</given-names></name><name><surname>Rachel</surname><given-names>RA</given-names></name><name><surname>Aleman</surname><given-names>TS</given-names></name><name><surname>Swider</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>SB</given-names></name><name><surname>Sumaroka</surname><given-names>A</given-names></name><name><surname>Roman</surname><given-names>AJ</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>1411</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr022</pub-id><pub-id pub-id-type="pmid">21245082</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collin</surname><given-names>RW</given-names></name><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>van der Velde-Visser</surname><given-names>SD</given-names></name><name><surname>Bennicelli</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>Cremers</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antisense oligonucleotide (AON) -based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>1</volume><elocation-id>e14</elocation-id><pub-id pub-id-type="doi">10.1038/mtna.2012.3</pub-id><pub-id pub-id-type="pmid">23343883</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppieters</surname><given-names>F</given-names></name><name><surname>Lefever</surname><given-names>S</given-names></name><name><surname>Leroy</surname><given-names>BP</given-names></name><name><surname>De Baere</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cep290, a gene with many faces: mutation overview and presentation of cep290base</article-title><source>Human Mutation</source><volume>31</volume><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1002/humu.21337</pub-id><pub-id pub-id-type="pmid">20690115</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>CS</given-names></name><name><surname>Renner</surname><given-names>M</given-names></name><name><surname>De Gennaro</surname><given-names>M</given-names></name><name><surname>Gross-Scherf</surname><given-names>B</given-names></name><name><surname>Goldblum</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Munz</surname><given-names>M</given-names></name><name><surname>Rodrigues</surname><given-names>TM</given-names></name><name><surname>Krol</surname><given-names>J</given-names></name><name><surname>Szikra</surname><given-names>T</given-names></name><name><surname>Cuttat</surname><given-names>R</given-names></name><name><surname>Waldt</surname><given-names>A</given-names></name><name><surname>Papasaikas</surname><given-names>P</given-names></name><name><surname>Diggelmann</surname><given-names>R</given-names></name><name><surname>Patino-Alvarez</surname><given-names>CP</given-names></name><name><surname>Galliker</surname><given-names>P</given-names></name><name><surname>Spirig</surname><given-names>SE</given-names></name><name><surname>Pavlinic</surname><given-names>D</given-names></name><name><surname>Gerber-Hollbach</surname><given-names>N</given-names></name><name><surname>Schuierer</surname><given-names>S</given-names></name><name><surname>Srdanovic</surname><given-names>A</given-names></name><name><surname>Balogh</surname><given-names>M</given-names></name><name><surname>Panero</surname><given-names>R</given-names></name><name><surname>Kusnyerik</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Stadler</surname><given-names>MB</given-names></name><name><surname>Orgül</surname><given-names>S</given-names></name><name><surname>Picelli</surname><given-names>S</given-names></name><name><surname>Hasler</surname><given-names>PW</given-names></name><name><surname>Hierlemann</surname><given-names>A</given-names></name><name><surname>Scholl</surname><given-names>HPN</given-names></name><name><surname>Roma</surname><given-names>G</given-names></name><name><surname>Nigsch</surname><given-names>F</given-names></name><name><surname>Roska</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell types of the human retina and its organoids at single-cell resolution</article-title><source>Cell</source><volume>182</volume><fpage>1623</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.013</pub-id><pub-id pub-id-type="pmid">32946783</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craige</surname><given-names>B</given-names></name><name><surname>Tsao</surname><given-names>CC</given-names></name><name><surname>Diener</surname><given-names>DR</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Lechtreck</surname><given-names>KF</given-names></name><name><surname>Rosenbaum</surname><given-names>JL</given-names></name><name><surname>Witman</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CEP290 tethers flagellar transition zone microtubules to the membrane and regulates flagellar protein content</article-title><source>The Journal of Cell Biology</source><volume>190</volume><fpage>927</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1083/jcb.201006105</pub-id><pub-id pub-id-type="pmid">20819941</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremers</surname><given-names>FPM</given-names></name><name><surname>Boon</surname><given-names>CJF</given-names></name><name><surname>Bujakowska</surname><given-names>K</given-names></name><name><surname>Zeitz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Special issue introduction: inherited retinal disease: novel candidate genes, genotype-phenotype correlations, and inheritance models</article-title><source>Genes</source><volume>9</volume><elocation-id>215</elocation-id><pub-id pub-id-type="doi">10.3390/genes9040215</pub-id><pub-id pub-id-type="pmid">29659558</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delamere</surname><given-names>NA</given-names></name><name><surname>Williams</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>The influence of reserpine and propranolol upon the IOP response to vanadate in the rabbit</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>26</volume><fpage>1442</fpage><lpage>1445</lpage><pub-id pub-id-type="pmid">3850082</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Yzer</surname><given-names>S</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Arends</surname><given-names>ML</given-names></name><name><surname>Voesenek</surname><given-names>KEJ</given-names></name><name><surname>Zonneveld</surname><given-names>MN</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Hoyng</surname><given-names>CB</given-names></name><name><surname>van den Born</surname><given-names>LI</given-names></name><name><surname>Rohrschneider</surname><given-names>K</given-names></name><name><surname>Cremers</surname><given-names>FPM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis</article-title><source>American Journal of Human Genetics</source><volume>79</volume><fpage>556</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1086/507318</pub-id><pub-id pub-id-type="pmid">16909394</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Cremers</surname><given-names>FPM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Leber congenital amaurosis: genes, proteins and disease mechanisms</article-title><source>Progress in Retinal and Eye Research</source><volume>27</volume><fpage>391</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2008.05.003</pub-id><pub-id pub-id-type="pmid">18632300</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiStefano</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Panebianco</surname><given-names>C</given-names></name><name><surname>Kaya</surname><given-names>KD</given-names></name><name><surname>Brooks</surname><given-names>MJ</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>NY</given-names></name><name><surname>Pohida</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Accelerated and improved differentiation of retinal organoids from pluripotent stem cells in rotating-wall vessel bioreactors</article-title><source>Stem Cell Reports</source><volume>10</volume><fpage>300</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.11.001</pub-id><pub-id pub-id-type="pmid">29233554</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>SJ</given-names></name><name><surname>McDougald</surname><given-names>DS</given-names></name><name><surname>Fisher</surname><given-names>KJ</given-names></name><name><surname>Bennicelli</surname><given-names>JL</given-names></name><name><surname>Mitchell</surname><given-names>LG</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spliceosome-Mediated pre-mRNA trans-splicing can repair CEP290 mRNA</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>12</volume><fpage>294</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2018.05.014</pub-id><pub-id pub-id-type="pmid">30195768</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drivas</surname><given-names>TG</given-names></name><name><surname>Holzbaur</surname><given-names>ELF</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disruption of CEP290 microtubule/membrane-binding domains causes retinal degeneration</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>4525</fpage><lpage>4539</lpage><pub-id pub-id-type="doi">10.1172/JCI69448</pub-id><pub-id pub-id-type="pmid">24051377</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drivas</surname><given-names>TG</given-names></name><name><surname>Wojno</surname><given-names>AP</given-names></name><name><surname>Tucker</surname><given-names>BA</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Basal exon skipping and genetic pleiotropy: a predictive model of disease pathogenesis</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>291ra97</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa5370</pub-id><pub-id pub-id-type="pmid">26062849</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulla</surname><given-names>K</given-names></name><name><surname>Aguila</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>A</given-names></name><name><surname>Jovanovic</surname><given-names>K</given-names></name><name><surname>Parfitt</surname><given-names>DA</given-names></name><name><surname>Schulkens</surname><given-names>I</given-names></name><name><surname>Chan</surname><given-names>HL</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Beumer</surname><given-names>W</given-names></name><name><surname>Vorthoren</surname><given-names>L</given-names></name><name><surname>Collin</surname><given-names>RWJ</given-names></name><name><surname>Garanto</surname><given-names>A</given-names></name><name><surname>Duijkers</surname><given-names>L</given-names></name><name><surname>Brugulat-Panes</surname><given-names>A</given-names></name><name><surname>Semo</surname><given-names>M</given-names></name><name><surname>Vugler</surname><given-names>AA</given-names></name><name><surname>Biasutto</surname><given-names>P</given-names></name><name><surname>Adamson</surname><given-names>P</given-names></name><name><surname>Cheetham</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c.2991+1655A &gt; G LCA10 models</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>12</volume><fpage>730</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2018.07.010</pub-id><pub-id pub-id-type="pmid">30114557</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engle</surname><given-names>SJ</given-names></name><name><surname>Puppala</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrating human pluripotent stem cells into drug development</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.05.011</pub-id><pub-id pub-id-type="pmid">23746976</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>S</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Balancing the photoreceptor proteome: proteostasis network therapeutics for inherited retinal disease</article-title><source>Genes</source><volume>10</volume><elocation-id>557</elocation-id><pub-id pub-id-type="doi">10.3390/genes10080557</pub-id><pub-id pub-id-type="pmid">31344897</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>GJ</given-names></name><name><surname>Carrigan</surname><given-names>M</given-names></name><name><surname>Dockery</surname><given-names>A</given-names></name><name><surname>Millington-Ward</surname><given-names>S</given-names></name><name><surname>Palfi</surname><given-names>A</given-names></name><name><surname>Chadderton</surname><given-names>N</given-names></name><name><surname>Humphries</surname><given-names>M</given-names></name><name><surname>Kiang</surname><given-names>AS</given-names></name><name><surname>Kenna</surname><given-names>PF</given-names></name><name><surname>Humphries</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Toward an elucidation of the molecular genetics of inherited retinal degenerations</article-title><source>Human Molecular Genetics</source><volume>26</volume><fpage>R2</fpage><lpage>R11</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx185</pub-id><pub-id pub-id-type="pmid">28510639</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraro</surname><given-names>S</given-names></name><name><surname>Gomez-Montalvo</surname><given-names>AI</given-names></name><name><surname>Olmos</surname><given-names>R</given-names></name><name><surname>Ramirez</surname><given-names>M</given-names></name><name><surname>Lamas</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Primary cilia in rat mature Müller glia: downregulation of IFT20 expression reduces sonic Hedgehog-mediated proliferation and dedifferentiation potential of Müller glia primary cultures</article-title><source>Cellular and Molecular Neurobiology</source><volume>35</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1007/s10571-014-0149-3</pub-id><pub-id pub-id-type="pmid">25504432</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Bravo-San Pedro</surname><given-names>JM</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles</article-title><source>Nature Reviews. Drug Discovery</source><volume>16</volume><fpage>487</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.22</pub-id><pub-id pub-id-type="pmid">28529316</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garafalo</surname><given-names>AV</given-names></name><name><surname>Cideciyan</surname><given-names>AV</given-names></name><name><surname>Héon</surname><given-names>E</given-names></name><name><surname>Sheplock</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>A</given-names></name><name><surname>WeiYang Yu</surname><given-names>C</given-names></name><name><surname>Sumaroka</surname><given-names>A</given-names></name><name><surname>Aguirre</surname><given-names>GD</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives</article-title><source>Progress in Retinal and Eye Research</source><volume>77</volume><elocation-id>100827</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2019.100827</pub-id><pub-id pub-id-type="pmid">31899291</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>KL</given-names></name><name><surname>Cideciyan</surname><given-names>AV</given-names></name><name><surname>Swider</surname><given-names>M</given-names></name><name><surname>Dufour</surname><given-names>VL</given-names></name><name><surname>Sumaroka</surname><given-names>A</given-names></name><name><surname>Komáromy</surname><given-names>AM</given-names></name><name><surname>Hauswirth</surname><given-names>WW</given-names></name><name><surname>Iwabe</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Beltran</surname><given-names>WA</given-names></name><name><surname>Aguirre</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long-Term structural outcomes of late-stage RPE65 gene therapy</article-title><source>Molecular Therapy</source><volume>28</volume><fpage>266</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.08.013</pub-id><pub-id pub-id-type="pmid">31604676</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>X</given-names></name><name><surname>Perrault</surname><given-names>I</given-names></name><name><surname>Hanein</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Bigot</surname><given-names>K</given-names></name><name><surname>Defoort-Delhemmes</surname><given-names>S</given-names></name><name><surname>Rio</surname><given-names>M</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Scherman</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name><name><surname>Kichler</surname><given-names>A</given-names></name><name><surname>Rozet</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>1</volume><elocation-id>e29</elocation-id><pub-id pub-id-type="doi">10.1038/mtna.2012.21</pub-id><pub-id pub-id-type="pmid">23344081</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanany</surname><given-names>M</given-names></name><name><surname>Rivolta</surname><given-names>C</given-names></name><name><surname>Sharon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases</article-title><source>PNAS</source><volume>117</volume><fpage>2710</fpage><lpage>2716</lpage><pub-id pub-id-type="doi">10.1073/pnas.1913179117</pub-id><pub-id pub-id-type="pmid">31964843</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hargrove-Grimes</surname><given-names>P</given-names></name><name><surname>Mondal</surname><given-names>AK</given-names></name><name><surname>Gumerson</surname><given-names>J</given-names></name><name><surname>Nellissery</surname><given-names>J</given-names></name><name><surname>Aponte</surname><given-names>AM</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Bonifacino</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of endocytosis-associated rabgef1 causes aberrant morphogenesis and altered autophagy in photoreceptors leading to retinal degeneration</article-title><source>PLOS Genetics</source><volume>16</volume><elocation-id>e1009259</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1009259</pub-id><pub-id pub-id-type="pmid">33362196</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation mechanisms and signaling pathways of autophagy</article-title><source>Annual Review of Genetics</source><volume>43</volume><fpage>67</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-102808-114910</pub-id><pub-id pub-id-type="pmid">19653858</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>P</given-names></name><name><surname>Aulner</surname><given-names>N</given-names></name><name><surname>Bickle</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>AM</given-names></name><name><surname>Nery</surname><given-names>ED</given-names></name><name><surname>Ebner</surname><given-names>D</given-names></name><name><surname>Montoya</surname><given-names>MC</given-names></name><name><surname>Östling</surname><given-names>P</given-names></name><name><surname>Pietiäinen</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>LS</given-names></name><name><surname>Shorte</surname><given-names>SL</given-names></name><name><surname>Turcatti</surname><given-names>G</given-names></name><name><surname>von Schantz</surname><given-names>C</given-names></name><name><surname>Carragher</surname><given-names>NO</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Screening out irrelevant cell-based models of disease</article-title><source>Nature Reviews. Drug Discovery</source><volume>15</volume><fpage>751</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.175</pub-id><pub-id pub-id-type="pmid">27616293</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iggo</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1960">1960</year><article-title>Preganglionic sympathetic activity in normal and in reserpine-treated cats</article-title><source>The Journal of Physiology</source><volume>150</volume><fpage>114</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1960.sp006377</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaraj</surname><given-names>GG</given-names></name><name><surname>Hipp</surname><given-names>MS</given-names></name><name><surname>Hartl</surname><given-names>FU</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional modules of the proteostasis network</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>12</volume><elocation-id>a033951</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a033951</pub-id><pub-id pub-id-type="pmid">30833457</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalliomäki</surname><given-names>JL</given-names></name><name><surname>Kasanen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>A new combination of hypotensive drugs (reserpine, dihydralazine, furosemide and triamterene) for the treatment of arterial hypertension without risk of hypopotassaemia</article-title><source>Current Therapeutic Research, Clinical and Experimental</source><volume>11</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">4980816</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>KD</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Brooks</surname><given-names>MJ</given-names></name><name><surname>Kelley</surname><given-names>RA</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>de Val</surname><given-names>N</given-names></name><name><surname>Drinnan</surname><given-names>CT</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Kruczek</surname><given-names>K</given-names></name><name><surname>Erceg</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Lukovic</surname><given-names>D</given-names></name><name><surname>Adlakha</surname><given-names>YK</given-names></name><name><surname>Welby</surname><given-names>E</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptome-Based molecular staging of human stem cell-derived retinal organoids uncovers accelerated photoreceptor differentiation by 9-cis retinal</article-title><source>Molecular Vision</source><volume>25</volume><fpage>663</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">31814692</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>RA</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Accelerated development of rod photoreceptors in retinal organoids derived from human pluripotent stem cells by supplementation with 9-cis retinal</article-title><source>STAR Protocols</source><volume>1</volume><elocation-id>100033</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2020.100033</pub-id><pub-id pub-id-type="pmid">32728670</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mtor: a pharmacologic target for autophagy regulation</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1172/JCI73939</pub-id><pub-id pub-id-type="pmid">25654547</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Yang</surname><given-names>H-J</given-names></name><name><surname>Brooks</surname><given-names>MJ</given-names></name><name><surname>Zelinger</surname><given-names>L</given-names></name><name><surname>Karakülah</surname><given-names>G</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Boleda</surname><given-names>A</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Giuste</surname><given-names>F</given-names></name><name><surname>Whitaker</surname><given-names>DT</given-names></name><name><surname>Walton</surname><given-names>A</given-names></name><name><surname>Villasmil</surname><given-names>R</given-names></name><name><surname>Barb</surname><given-names>JJ</given-names></name><name><surname>Munson</surname><given-names>PJ</given-names></name><name><surname>Kaya</surname><given-names>KD</given-names></name><name><surname>Chaitankar</surname><given-names>V</given-names></name><name><surname>Cogliati</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NRL-regulated transcriptome dynamics of developing rod photoreceptors</article-title><source>Cell Reports</source><volume>17</volume><fpage>2460</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.074</pub-id><pub-id pub-id-type="pmid">27880916</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Eupatilin rescues ciliary transition zone defects to ameliorate ciliopathy-related phenotypes</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>3642</fpage><lpage>3648</lpage><pub-id pub-id-type="doi">10.1172/JCI99232</pub-id><pub-id pub-id-type="pmid">30035750</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaips</surname><given-names>CL</given-names></name><name><surname>Jayaraj</surname><given-names>GG</given-names></name><name><surname>Hartl</surname><given-names>FU</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pathways of cellular proteostasis in aging and disease</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>51</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709072</pub-id><pub-id pub-id-type="pmid">29127110</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kost-Alimova</surname><given-names>M</given-names></name><name><surname>Sidhom</surname><given-names>E-H</given-names></name><name><surname>Satyam</surname><given-names>A</given-names></name><name><surname>Chamberlain</surname><given-names>BT</given-names></name><name><surname>Dvela-Levitt</surname><given-names>M</given-names></name><name><surname>Melanson</surname><given-names>M</given-names></name><name><surname>Alper</surname><given-names>SL</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Gutierrez</surname><given-names>J</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>PJ</given-names></name><name><surname>Grinkevich</surname><given-names>E</given-names></name><name><surname>Reyes-Bricio</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>AR</given-names></name><name><surname>Watts</surname><given-names>AJB</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Pablo</surname><given-names>JL</given-names></name><name><surname>Coraor</surname><given-names>J</given-names></name><name><surname>Roignot</surname><given-names>J</given-names></name><name><surname>Vernon</surname><given-names>KA</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Emani</surname><given-names>M</given-names></name><name><surname>Racette</surname><given-names>M</given-names></name><name><surname>Bazua-Valenti</surname><given-names>S</given-names></name><name><surname>Padovano</surname><given-names>V</given-names></name><name><surname>Weins</surname><given-names>A</given-names></name><name><surname>McAdoo</surname><given-names>SP</given-names></name><name><surname>Tam</surname><given-names>FWK</given-names></name><name><surname>Ronco</surname><given-names>L</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name><name><surname>Shaw</surname><given-names>JL</given-names></name><name><surname>Greka</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A high-content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury</article-title><source>Cell Reports. Medicine</source><volume>1</volume><elocation-id>100137</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100137</pub-id><pub-id pub-id-type="pmid">33294858</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kralj</surname><given-names>M</given-names></name><name><surname>Pipan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Accumulation of membranes and photoreceptor degeneration in mouse retina</article-title><source>Folia Morphologica</source><volume>57</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">10437310</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruczek</surname><given-names>K</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pluripotent stem cell-derived retinal organoids for disease modeling and development of therapies</article-title><source>Stem Cells</source><volume>38</volume><fpage>1206</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1002/stem.3239</pub-id><pub-id pub-id-type="pmid">32506758</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruiswijk</surname><given-names>F</given-names></name><name><surname>Labuschagne</surname><given-names>CF</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>P53 in survival, death and metabolic health: a lifeguard with a licence to kill</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>16</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nrm4007</pub-id><pub-id pub-id-type="pmid">26122615</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>AV</given-names></name><name><surname>Mills</surname><given-names>J</given-names></name><name><surname>Lapierre</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Selective autophagy receptor p62/SQSTM1, a pivotal player in stress and aging</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>793328</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.793328</pub-id><pub-id pub-id-type="pmid">35237597</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>YS</given-names></name><name><surname>Pandey</surname><given-names>UB</given-names></name><name><surname>Kaushik</surname><given-names>S</given-names></name><name><surname>Tresse</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>JP</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name><name><surname>Yao</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy</article-title><source>The EMBO Journal</source><volume>29</volume><fpage>969</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.405</pub-id><pub-id pub-id-type="pmid">20075865</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KI</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Namkoong</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>WK</given-names></name><name><surname>Park</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux</article-title><source>Biochemical and Biophysical Research Communications</source><volume>462</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.04.145</pub-id><pub-id pub-id-type="pmid">25976674</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroy</surname><given-names>BP</given-names></name><name><surname>Birch</surname><given-names>DG</given-names></name><name><surname>Duncan</surname><given-names>JL</given-names></name><name><surname>Lam</surname><given-names>BL</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Porto</surname><given-names>FBO</given-names></name><name><surname>Russell</surname><given-names>SR</given-names></name><name><surname>Girach</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Leber congenital amaurosis due to CEP290 mutations-severe vision impairment with a high unmet medical need: a review</article-title><source>Retina</source><volume>41</volume><fpage>898</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1097/IAE.0000000000003133</pub-id><pub-id pub-id-type="pmid">33595255</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>WF</given-names></name><name><surname>Guo</surname><given-names>LJ</given-names></name><name><surname>Xu</surname><given-names>ZG</given-names></name><name><surname>Wu</surname><given-names>HL</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>P62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation</article-title><source>Cellular &amp; Molecular Biology Letters</source><volume>21</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1186/s11658-016-0031-z</pub-id><pub-id pub-id-type="pmid">28536631</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Leslie</surname><given-names>PL</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Life and death decision-making by p53 and implications for cancer immunotherapy</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>226</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.10.005</pub-id><pub-id pub-id-type="pmid">33199193</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>A</given-names></name><name><surname>Benhar</surname><given-names>I</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The retina as a window to the brain-from eye research to CNS disorders</article-title><source>Nature Reviews. Neurology</source><volume>9</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2012.227</pub-id><pub-id pub-id-type="pmid">23165340</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEwen</surname><given-names>DP</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name><name><surname>Jenkins</surname><given-names>PM</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons</article-title><source>PNAS</source><volume>104</volume><fpage>15917</fpage><lpage>15922</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704140104</pub-id><pub-id pub-id-type="pmid">17898177</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalska-Małecka</surname><given-names>K</given-names></name><name><surname>Kabiesz</surname><given-names>A</given-names></name><name><surname>Kimsa</surname><given-names>MW</given-names></name><name><surname>Strzałka-Mrozik</surname><given-names>B</given-names></name><name><surname>Formińska-Kapuścik</surname><given-names>M</given-names></name><name><surname>Nita</surname><given-names>M</given-names></name><name><surname>Mazurek</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration</article-title><source>Clinical Interventions in Aging</source><volume>11</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.2147/CIA.S93820</pub-id><pub-id pub-id-type="pmid">27069359</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>RJ</given-names></name><name><surname>Parker</surname><given-names>BL</given-names></name><name><surname>Quaife-Ryan</surname><given-names>GA</given-names></name><name><surname>Voges</surname><given-names>HK</given-names></name><name><surname>Needham</surname><given-names>EJ</given-names></name><name><surname>Bornot</surname><given-names>A</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>H</given-names></name><name><surname>Polla</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>DA</given-names></name><name><surname>Drowley</surname><given-names>L</given-names></name><name><surname>Clausen</surname><given-names>M</given-names></name><name><surname>Plowright</surname><given-names>AT</given-names></name><name><surname>Barrett</surname><given-names>IP</given-names></name><name><surname>Wang</surname><given-names>Q-D</given-names></name><name><surname>James</surname><given-names>DE</given-names></name><name><surname>Porrello</surname><given-names>ER</given-names></name><name><surname>Hudson</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>895</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.03.009</pub-id><pub-id pub-id-type="pmid">30930147</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Autophagy: process and function</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>2861</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1101/gad.1599207</pub-id><pub-id pub-id-type="pmid">18006683</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mookherjee</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Isgrig</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Hiriyanna</surname><given-names>S</given-names></name><name><surname>Levron</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Colosi</surname><given-names>P</given-names></name><name><surname>Chien</surname><given-names>W</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A CEP290 C-terminal domain complements the mutant CEP290 of rd16 mice in trans and rescues retinal degeneration</article-title><source>Cell Reports</source><volume>25</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.043</pub-id><pub-id pub-id-type="pmid">30332642</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name><name><surname>Takata</surname><given-names>N</given-names></name><name><surname>Kawada</surname><given-names>M</given-names></name><name><surname>Muguruma</surname><given-names>K</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Yonemura</surname><given-names>S</given-names></name><name><surname>Eiraku</surname><given-names>M</given-names></name><name><surname>Sasai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Self-formation of optic CUPS and storable stratified neural retina from human escs</article-title><source>Cell Stem Cell</source><volume>10</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.05.009</pub-id><pub-id pub-id-type="pmid">22704518</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Effects of various pharmacologic agents on allergic inflammation of the eye. The roles of chemical mediators in ocular inflammation</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>19</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">6101322</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palko</surname><given-names>SI</given-names></name><name><surname>Saba</surname><given-names>NJ</given-names></name><name><surname>Mullane</surname><given-names>E</given-names></name><name><surname>Nicholas</surname><given-names>BD</given-names></name><name><surname>Nagasaka</surname><given-names>Y</given-names></name><name><surname>Ambati</surname><given-names>J</given-names></name><name><surname>Gelfand</surname><given-names>BD</given-names></name><name><surname>Ishigami</surname><given-names>A</given-names></name><name><surname>Bargagna-Mohan</surname><given-names>P</given-names></name><name><surname>Mohan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Compartmentalized citrullination in Muller glial endfeet during retinal degeneration</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2121875119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2121875119</pub-id><pub-id pub-id-type="pmid">35197297</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pampliega</surname><given-names>O</given-names></name><name><surname>Orhon</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Díaz-Carretero</surname><given-names>A</given-names></name><name><surname>Beau</surname><given-names>I</given-names></name><name><surname>Codogno</surname><given-names>P</given-names></name><name><surname>Satir</surname><given-names>BH</given-names></name><name><surname>Satir</surname><given-names>P</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional interaction between autophagy and ciliogenesis</article-title><source>Nature</source><volume>502</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature12639</pub-id><pub-id pub-id-type="pmid">24089209</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parfitt</surname><given-names>DA</given-names></name><name><surname>Lane</surname><given-names>A</given-names></name><name><surname>Ramsden</surname><given-names>CM</given-names></name><name><surname>Carr</surname><given-names>AJF</given-names></name><name><surname>Munro</surname><given-names>PM</given-names></name><name><surname>Jovanovic</surname><given-names>K</given-names></name><name><surname>Schwarz</surname><given-names>N</given-names></name><name><surname>Kanuga</surname><given-names>N</given-names></name><name><surname>Muthiah</surname><given-names>MN</given-names></name><name><surname>Hull</surname><given-names>S</given-names></name><name><surname>Gallo</surname><given-names>JM</given-names></name><name><surname>da Cruz</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name><name><surname>Hardcastle</surname><given-names>AJ</given-names></name><name><surname>Coffey</surname><given-names>PJ</given-names></name><name><surname>Cheetham</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification and correction of mechanisms underlying inherited blindness in human ipsc-derived optic CUPS</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.03.021</pub-id><pub-id pub-id-type="pmid">27151457</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>EA</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The status of RPE65 gene therapy trials: safety and efficacy</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>5</volume><elocation-id>a017285</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a017285</pub-id><pub-id pub-id-type="pmid">25635059</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>SL</given-names></name><name><surname>Tkach</surname><given-names>J</given-names></name><name><surname>Gheiratmand</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Morrison</surname><given-names>CG</given-names></name><name><surname>Pelletier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Aggresome assembly at the centrosome is driven by CP110-CEP97-CEP290 and centriolar satellites</article-title><source>Nature Cell Biology</source><volume>24</volume><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-00869-0</pub-id><pub-id pub-id-type="pmid">35411088</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugacheva</surname><given-names>EN</given-names></name><name><surname>Jablonski</surname><given-names>SA</given-names></name><name><surname>Hartman</surname><given-names>TR</given-names></name><name><surname>Henske</surname><given-names>EP</given-names></name><name><surname>Golemis</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>HEF1-dependent Aurora A activation induces disassembly of the primary cilium</article-title><source>Cell</source><volume>129</volume><fpage>1351</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.04.035</pub-id><pub-id pub-id-type="pmid">17604723</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Zacks</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Shifting the balance of autophagy and proteasome activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor homeostasis</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>547</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1780-1</pub-id><pub-id pub-id-type="pmid">31320609</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachel</surname><given-names>RA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Photoreceptor sensory cilia and ciliopathies: focus on CEP290, RPGR and their interacting proteins</article-title><source>Cilia</source><volume>1</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/2046-2530-1-22</pub-id><pub-id pub-id-type="pmid">23351659</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachel</surname><given-names>RA</given-names></name><name><surname>Yamamoto</surname><given-names>EA</given-names></name><name><surname>Dewanjee</surname><given-names>MK</given-names></name><name><surname>May-Simera</surname><given-names>HL</given-names></name><name><surname>Sergeev</surname><given-names>YV</given-names></name><name><surname>Hackett</surname><given-names>AN</given-names></name><name><surname>Pohida</surname><given-names>K</given-names></name><name><surname>Munasinghe</surname><given-names>J</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Wickstead</surname><given-names>B</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cep290 alleles in mice disrupt tissue-specific cilia biogenesis and recapitulate features of syndromic ciliopathies</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>3775</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv123</pub-id><pub-id pub-id-type="pmid">25859007</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raudvere</surname><given-names>U</given-names></name><name><surname>Kolberg</surname><given-names>L</given-names></name><name><surname>Kuzmin</surname><given-names>I</given-names></name><name><surname>Arak</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>H</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>G: profiler: a web server for functional enrichment analysis and conversions of gene Lists (2019 update)</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W191</fpage><lpage>W198</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz369</pub-id><pub-id pub-id-type="pmid">31066453</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regent</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Kelley</surname><given-names>RA</given-names></name><name><surname>Qu</surname><given-names>Z</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A simple and efficient method for generating human retinal organoids</article-title><source>Molecular Vision</source><volume>26</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">32174751</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regent</surname><given-names>F</given-names></name><name><surname>Batz</surname><given-names>Z</given-names></name><name><surname>Kelley</surname><given-names>RA</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nicotinamide promotes formation of retinal organoids from human pluripotent stem cells via enhanced neural cell fate commitment</article-title><source>Frontiers in Cellular Neuroscience</source><volume>16</volume><elocation-id>878351</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2022.878351</pub-id><pub-id pub-id-type="pmid">35783089</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>JF</given-names></name><name><surname>Leroux</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genes and molecular pathways underpinning ciliopathies</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>533</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.60</pub-id><pub-id pub-id-type="pmid">28698599</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotsos</surname><given-names>T</given-names></name><name><surname>Symeonidis</surname><given-names>C</given-names></name><name><surname>Triantafillopoulou</surname><given-names>I</given-names></name><name><surname>Kanellopoulos</surname><given-names>S</given-names></name><name><surname>Kouris</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye</article-title><source>International Ophthalmology</source><volume>34</volume><fpage>1271</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1007/s10792-014-9921-0</pub-id><pub-id pub-id-type="pmid">25192913</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouvas</surname><given-names>A</given-names></name><name><surname>Liarakos</surname><given-names>VS</given-names></name><name><surname>Theodossiadis</surname><given-names>P</given-names></name><name><surname>Papathanassiou</surname><given-names>M</given-names></name><name><surname>Petrou</surname><given-names>P</given-names></name><name><surname>Ladas</surname><given-names>I</given-names></name><name><surname>Vergados</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration</article-title><source>Ophthalmologica. Journal International d’ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde</source><volume>223</volume><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1159/000228590</pub-id><pub-id pub-id-type="pmid">19602910</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>A</given-names></name><name><surname>Capowski</surname><given-names>E</given-names></name><name><surname>Fernandez Zepeda</surname><given-names>MA</given-names></name><name><surname>Nelson</surname><given-names>EC</given-names></name><name><surname>Gamm</surname><given-names>DM</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cone photoreceptors in human stem cell-derived retinal organoids demonstrate intrinsic light responses that mimic those of primate fovea</article-title><source>Cell Stem Cell</source><volume>29</volume><fpage>460</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.01.002</pub-id><pub-id pub-id-type="pmid">35104442</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Next-Generation regenerative medicine: organogenesis from stem cells in 3D culture</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>520</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.04.009</pub-id><pub-id pub-id-type="pmid">23642363</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Otto</surname><given-names>EA</given-names></name><name><surname>O’Toole</surname><given-names>JF</given-names></name><name><surname>Nurnberg</surname><given-names>G</given-names></name><name><surname>Kennedy</surname><given-names>MA</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Hennies</surname><given-names>HC</given-names></name><name><surname>Helou</surname><given-names>J</given-names></name><name><surname>Attanasio</surname><given-names>M</given-names></name><name><surname>Fausett</surname><given-names>BV</given-names></name><name><surname>Utsch</surname><given-names>B</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Drummond</surname><given-names>I</given-names></name><name><surname>Kawakami</surname><given-names>I</given-names></name><name><surname>Kusakabe</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Larson</surname><given-names>RG</given-names></name><name><surname>Allen</surname><given-names>SJ</given-names></name><name><surname>Wilkinson</surname><given-names>CJ</given-names></name><name><surname>Nigg</surname><given-names>EA</given-names></name><name><surname>Shou</surname><given-names>C</given-names></name><name><surname>Lillo</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>DS</given-names></name><name><surname>Hoppe</surname><given-names>B</given-names></name><name><surname>Kemper</surname><given-names>MJ</given-names></name><name><surname>Neuhaus</surname><given-names>T</given-names></name><name><surname>Parisi</surname><given-names>MA</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Petry</surname><given-names>M</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Gloy</surname><given-names>J</given-names></name><name><surname>Ganner</surname><given-names>A</given-names></name><name><surname>Walz</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Nurnberg</surname><given-names>P</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Leroux</surname><given-names>MR</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4</article-title><source>Nature Genetics</source><volume>38</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1038/ng1786</pub-id><pub-id pub-id-type="pmid">16682973</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>HPN</given-names></name><name><surname>Strauss</surname><given-names>RW</given-names></name><name><surname>Singh</surname><given-names>MS</given-names></name><name><surname>Dalkara</surname><given-names>D</given-names></name><name><surname>Roska</surname><given-names>B</given-names></name><name><surname>Picaud</surname><given-names>S</given-names></name><name><surname>Sahel</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging therapies for inherited retinal degeneration</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>368rv6</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf2838</pub-id><pub-id pub-id-type="pmid">27928030</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Kutsyr</surname><given-names>O</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Bolz</surname><given-names>S</given-names></name><name><surname>Arango-Gonzalez</surname><given-names>B</given-names></name><name><surname>Ueffing</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pharmacological inhibition of the VCP/proteasome axis rescues photoreceptor degeneration in rhop23h rat retinal explants</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>1528</elocation-id><pub-id pub-id-type="doi">10.3390/biom11101528</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Insinna-Kettenhofen</surname><given-names>C</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>English</surname><given-names>MA</given-names></name><name><surname>Semler</surname><given-names>EM</given-names></name><name><surname>Mahgerefteh</surname><given-names>J</given-names></name><name><surname>Cideciyan</surname><given-names>AV</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Brooks</surname><given-names>BP</given-names></name><name><surname>Gunay-Aygun</surname><given-names>M</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Cogliati</surname><given-names>T</given-names></name><name><surname>Westlake</surname><given-names>CJ</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In vitro modeling using ciliopathy-patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations</article-title><source>Cell Reports</source><volume>20</volume><fpage>384</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.045</pub-id><pub-id pub-id-type="pmid">28700940</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simões-Pires</surname><given-names>C</given-names></name><name><surname>Zwick</surname><given-names>V</given-names></name><name><surname>Nurisso</surname><given-names>A</given-names></name><name><surname>Schenker</surname><given-names>E</given-names></name><name><surname>Carrupt</surname><given-names>P-A</given-names></name><name><surname>Cuendet</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hdac6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?</article-title><source>Molecular Neurodegeneration</source><volume>8</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/1750-1326-8-7</pub-id><pub-id pub-id-type="pmid">23356410</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sridhar</surname><given-names>A</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name><name><surname>Finkbeiner</surname><given-names>CR</given-names></name><name><surname>Chitsazan</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Haugan</surname><given-names>AK</given-names></name><name><surname>Eschenbacher</surname><given-names>KM</given-names></name><name><surname>Jackson</surname><given-names>DL</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Bermingham-McDonogh</surname><given-names>O</given-names></name><name><surname>Glass</surname><given-names>I</given-names></name><name><surname>Reh</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-Cell transcriptomic comparison of human fetal retina, hpsc-derived retinal organoids, and long-term retinal cultures</article-title><source>Cell Reports</source><volume>30</volume><fpage>1644</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.01.007</pub-id><pub-id pub-id-type="pmid">32023475</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struzyna</surname><given-names>LA</given-names></name><name><surname>Watt</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The emerging role of neuronal organoid models in drug discovery: potential applications and hurdles to implementation</article-title><source>Molecular Pharmacology</source><volume>99</volume><fpage>256</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1124/molpharm.120.000142</pub-id><pub-id pub-id-type="pmid">33547249</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Nastou</surname><given-names>KC</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Kirsch</surname><given-names>R</given-names></name><name><surname>Pyysalo</surname><given-names>S</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Legeay</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The string database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D605</fpage><lpage>D612</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id><pub-id pub-id-type="pmid">33237311</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tambuyzer</surname><given-names>E</given-names></name><name><surname>Vandendriessche</surname><given-names>B</given-names></name><name><surname>Austin</surname><given-names>CP</given-names></name><name><surname>Brooks</surname><given-names>PJ</given-names></name><name><surname>Larsson</surname><given-names>K</given-names></name><name><surname>Miller Needleman</surname><given-names>KI</given-names></name><name><surname>Valentine</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>K</given-names></name><name><surname>Groft</surname><given-names>SC</given-names></name><name><surname>Preti</surname><given-names>R</given-names></name><name><surname>Oprea</surname><given-names>TI</given-names></name><name><surname>Prunotto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapies for rare diseases: therapeutic modalities, progress and challenges ahead</article-title><source>Nature Reviews. Drug Discovery</source><volume>19</volume><fpage>93</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0049-9</pub-id><pub-id pub-id-type="pmid">31836861</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>MG</given-names></name><name><surname>Stowe</surname><given-names>TR</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Stearns</surname><given-names>T</given-names></name><name><surname>Franco</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites</article-title><source>Nature</source><volume>502</volume><fpage>254</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nature12606</pub-id><pub-id pub-id-type="pmid">24089205</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolone</surname><given-names>A</given-names></name><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ueffing</surname><given-names>M</given-names></name><name><surname>Arango-Gonzalez</surname><given-names>B</given-names></name><name><surname>Paquet-Durand</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pathomechanisms of inherited retinal degeneration and perspectives for neuroprotection</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>1</volume><elocation-id>a041310</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a041310</pub-id><pub-id pub-id-type="pmid">36122932</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Bull</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>W</given-names></name><name><surname>Kotoda</surname><given-names>Y</given-names></name><name><surname>Talukdar</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>LEH</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Müller glial responses compensate for degenerating photoreceptors in retinitis pigmentosa</article-title><source>Experimental &amp; Molecular Medicine</source><volume>53</volume><fpage>1748</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00693-w</pub-id><pub-id pub-id-type="pmid">34799683</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toulis</surname><given-names>V</given-names></name><name><surname>García-Monclús</surname><given-names>S</given-names></name><name><surname>de la Peña-Ramírez</surname><given-names>C</given-names></name><name><surname>Arenas-Galnares</surname><given-names>R</given-names></name><name><surname>Abril</surname><given-names>JF</given-names></name><name><surname>Todi</surname><given-names>SV</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Garanto</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>MDC</given-names></name><name><surname>Marfany</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The deubiquitinating enzyme ataxin-3 regulates ciliogenesis and phagocytosis in the retina</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108360</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108360</pub-id><pub-id pub-id-type="pmid">33176149</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>WY</given-names></name><name><surname>Bossard</surname><given-names>C</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name><name><surname>Peränen</surname><given-names>J</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Malhotra</surname><given-names>V</given-names></name><name><surname>Dynlacht</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cp110 suppresses primary cilia formation through its interaction with CEP290, a protein deficient in human ciliary disease</article-title><source>Developmental Cell</source><volume>15</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2008.07.004</pub-id><pub-id pub-id-type="pmid">18694559</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Silhavy</surname><given-names>JL</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Barrano</surname><given-names>G</given-names></name><name><surname>Krishnaswami</surname><given-names>SR</given-names></name><name><surname>Castori</surname><given-names>M</given-names></name><name><surname>Lancaster</surname><given-names>MA</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Boccone</surname><given-names>L</given-names></name><name><surname>Al-Gazali</surname><given-names>L</given-names></name><name><surname>Fazzi</surname><given-names>E</given-names></name><name><surname>Signorini</surname><given-names>S</given-names></name><name><surname>Louie</surname><given-names>CM</given-names></name><name><surname>Bellacchio</surname><given-names>E</given-names></name><collab>International Joubert Syndrome Related Disorders Study Group</collab><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome</article-title><source>Nature Genetics</source><volume>38</volume><fpage>623</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/ng1805</pub-id><pub-id pub-id-type="pmid">16682970</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veleri</surname><given-names>S</given-names></name><name><surname>Lazar</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Sieving</surname><given-names>PA</given-names></name><name><surname>Banin</surname><given-names>E</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Biology and therapy of inherited retinal degenerative disease: insights from mouse models</article-title><source>Disease Models &amp; Mechanisms</source><volume>8</volume><fpage>109</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1242/dmm.017913</pub-id><pub-id pub-id-type="pmid">25650393</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>YZ</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Rüegg</surname><given-names>MA</given-names></name><name><surname>Punzo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activated mtorc1 promotes long-term cone survival in retinitis pigmentosa mice</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>1446</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1172/JCI79766</pub-id><pub-id pub-id-type="pmid">25798619</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Punzo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tsc but not PTEN loss in starving cones of retinitis pigmentosa mice leads to an autophagy defect and mTORC1 dissociation from the lysosome</article-title><source>Cell Death &amp; Disease</source><volume>7</volume><elocation-id>e2279</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.182</pub-id><pub-id pub-id-type="pmid">27362797</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbakel</surname><given-names>SK</given-names></name><name><surname>van Huet</surname><given-names>RAC</given-names></name><name><surname>Boon</surname><given-names>CJF</given-names></name><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>Collin</surname><given-names>RWJ</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Hoyng</surname><given-names>CB</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Klevering</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Non-Syndromic retinitis pigmentosa</article-title><source>Progress in Retinal and Eye Research</source><volume>66</volume><fpage>157</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2018.03.005</pub-id><pub-id pub-id-type="pmid">29597005</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergara</surname><given-names>MN</given-names></name><name><surname>Flores-Bellver</surname><given-names>M</given-names></name><name><surname>Aparicio-Domingo</surname><given-names>S</given-names></name><name><surname>McNally</surname><given-names>M</given-names></name><name><surname>Wahlin</surname><given-names>KJ</given-names></name><name><surname>Saxena</surname><given-names>MT</given-names></name><name><surname>Mumm</surname><given-names>JS</given-names></name><name><surname>Canto-Soler</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Three-Dimensional automated reporter quantification (3D-ARQ) technology enables quantitative screening in retinal organoids</article-title><source>Development</source><volume>144</volume><fpage>3698</fpage><lpage>3705</lpage><pub-id pub-id-type="doi">10.1242/dev.146290</pub-id><pub-id pub-id-type="pmid">28870990</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vessey</surname><given-names>KA</given-names></name><name><surname>Jobling</surname><given-names>AI</given-names></name><name><surname>Tran</surname><given-names>MX</given-names></name><name><surname>Wang</surname><given-names>AY</given-names></name><name><surname>Greferath</surname><given-names>U</given-names></name><name><surname>Fletcher</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Treatments targeting autophagy ameliorate the age-related macular degeneration phenotype in mice lacking ApoE (apolipoprotein E)</article-title><source>Autophagy</source><volume>18</volume><fpage>2368</fpage><lpage>2384</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2034131</pub-id><pub-id pub-id-type="pmid">35196199</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jadhav</surname><given-names>A</given-names></name><name><surname>Southal</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A grid algorithm for high throughput fitting of dose-response curve data</article-title><source>Current Chemical Genomics</source><volume>4</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2174/1875397301004010057</pub-id><pub-id pub-id-type="pmid">21331310</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>J</given-names></name><name><surname>Gaur</surname><given-names>M</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Proteostasis in aging-associated ocular disease</article-title><source>Molecular Aspects of Medicine</source><volume>88</volume><elocation-id>101157</elocation-id><pub-id pub-id-type="doi">10.1016/j.mam.2022.101157</pub-id><pub-id pub-id-type="pmid">36459837</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsbie</surname><given-names>DS</given-names></name><name><surname>Mitchell</surname><given-names>KL</given-names></name><name><surname>Jaskula-Ranga</surname><given-names>V</given-names></name><name><surname>Sluch</surname><given-names>VM</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Buehler</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>SE</given-names></name><name><surname>Zhang</surname><given-names>PW</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Hamed</surname><given-names>E</given-names></name><name><surname>Chamling</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>IDC</given-names></name><name><surname>Ronai</surname><given-names>ZA</given-names></name><name><surname>Berlinicke</surname><given-names>CA</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Enhanced functional genomic screening identifies novel mediators of dual leucine zipper kinase-dependent injury signaling in neurons</article-title><source>Neuron</source><volume>94</volume><fpage>1142</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.06.008</pub-id><pub-id pub-id-type="pmid">28641113</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Chakarova</surname><given-names>CF</given-names></name><name><surname>Abd El-Aziz</surname><given-names>MM</given-names></name><name><surname>Bhattacharya</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait</article-title><source>Nature Reviews. Genetics</source><volume>11</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/nrg2717</pub-id><pub-id pub-id-type="pmid">20212494</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Pang</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cep290 is essential for the initiation of ciliary transition zone assembly</article-title><source>PLOS Biology</source><volume>18</volume><elocation-id>e3001034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001034</pub-id><pub-id pub-id-type="pmid">33370260</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wylie</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>AE</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>WJ</given-names></name><name><surname>Abrams</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Distinct p53 isoforms code for opposing transcriptional outcomes</article-title><source>Developmental Cell</source><volume>57</volume><fpage>1833</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2022.06.015</pub-id><pub-id pub-id-type="pmid">35820415</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Autophagy and ciliogenesis</article-title><source>JMA Journal</source><volume>4</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.31662/jmaj.2021-0090</pub-id><pub-id pub-id-type="pmid">34414314</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Frontera</surname><given-names>E</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>NW</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name><name><surname>Ferguson</surname><given-names>TA</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Zacks</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibiting autophagy reduces retinal degeneration caused by protein misfolding</article-title><source>Autophagy</source><volume>14</volume><fpage>1226</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1080/15548627.2018.1463121</pub-id><pub-id pub-id-type="pmid">29940785</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yohn</surname><given-names>CN</given-names></name><name><surname>Gergues</surname><given-names>MM</given-names></name><name><surname>Samuels</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of 5-HT receptors in depression</article-title><source>Molecular Brain</source><volume>10</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/s13041-017-0306-y</pub-id><pub-id pub-id-type="pmid">28646910</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaninello</surname><given-names>M</given-names></name><name><surname>Palikaras</surname><given-names>K</given-names></name><name><surname>Naon</surname><given-names>D</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name><name><surname>Herkenne</surname><given-names>S</given-names></name><name><surname>Quintana-Cabrera</surname><given-names>R</given-names></name><name><surname>Semenzato</surname><given-names>M</given-names></name><name><surname>Grespi</surname><given-names>F</given-names></name><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Tavernarakis</surname><given-names>N</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4029</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17821-1</pub-id><pub-id pub-id-type="pmid">32788597</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelinger</surname><given-names>L</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rna biology in retinal development and disease</article-title><source>Trends in Genetics</source><volume>34</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2018.01.002</pub-id><pub-id pub-id-type="pmid">29395379</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Lilley</surname><given-names>B</given-names></name><name><surname>Berlinicke</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Shou</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Mulligan</surname><given-names>T</given-names></name><name><surname>Emmerich</surname><given-names>K</given-names></name><name><surname>Saxena</surname><given-names>MT</given-names></name><name><surname>Hall</surname><given-names>KR</given-names></name><name><surname>Sharrock</surname><given-names>AV</given-names></name><name><surname>Brandon</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kam</surname><given-names>T-I</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Shim</surname><given-names>JS</given-names></name><name><surname>Hanes</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>JO</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Ackerley</surname><given-names>DF</given-names></name><name><surname>Rohrer</surname><given-names>B</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Mumm</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Large-Scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa</article-title><source>eLife</source><volume>10</volume><elocation-id>e57245</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.57245</pub-id><pub-id pub-id-type="pmid">34184634</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Presswalla</surname><given-names>F</given-names></name><name><surname>Ali</surname><given-names>RR</given-names></name><name><surname>Zacks</surname><given-names>DN</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Miller</surname><given-names>JML</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration</article-title><source>Aging</source><volume>13</volume><fpage>10866</fpage><lpage>10890</lpage><pub-id pub-id-type="doi">10.18632/aging.202974</pub-id><pub-id pub-id-type="pmid">33872219</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>T</given-names></name><name><surname>Hampton</surname><given-names>C</given-names></name><name><surname>Vergara</surname><given-names>MN</given-names></name><name><surname>Cao</surname><given-names>L-H</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>TS</given-names></name><name><surname>Zambidis</surname><given-names>ET</given-names></name><name><surname>Meyer</surname><given-names>JS</given-names></name><name><surname>Gamm</surname><given-names>DM</given-names></name><name><surname>Yau</surname><given-names>K-W</given-names></name><name><surname>Canto-Soler</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4047</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5047</pub-id><pub-id pub-id-type="pmid">24915161</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlotcavitch</surname><given-names>L</given-names></name><name><surname>Flynn</surname><given-names>HW</given-names></name><name><surname>Avery</surname><given-names>RL</given-names></name><name><surname>Rachitskaya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy</article-title><source>Clinical Ophthalmology</source><volume>9</volume><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2147/OPTH.S69466</pub-id><pub-id pub-id-type="pmid">25609907</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Key Resource Table</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="top"><italic>Nrl</italic>-GFP WT</td><td align="left" valign="top">PMID: 27667917</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from mouse embryonic fibroblasts by lentivirus carrying Yamanaka factors</td></tr><tr><td align="left" valign="top">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="top"><italic>Nrl</italic>-GFP rd16 line 1</td><td align="left" valign="top">PMID: 30332642</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from mouse embryonic fibroblasts by lentivirus carrying Yamanaka factors</td></tr><tr><td align="left" valign="top">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="top"><italic>Nrl</italic>-GFP rd16 line 2</td><td align="left" valign="top">PMID: 30332642</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from mouse embryonic fibroblasts by lentivirus carrying Yamanaka factors</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="top">Control</td><td align="left" valign="top">PMID: 28700940</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from control fibroblasts by Sendai virus carrying Yamanaka factors</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="top">LCA-1</td><td align="left" valign="top">PMID: 28700940</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from control fibroblasts by Sendai virus carrying Yamanaka factors</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="top">LCA-2</td><td align="left" valign="top">In this paper</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from control fibroblasts by Sendai virus carrying Yamanaka factors and maintained in Swaroop lab in National Eye Institute, National Institutes of Health, United States</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="top">LCA-1-clone C</td><td align="left" valign="top">In this paper</td><td align="left" valign="top"/><td align="left" valign="top">Reprogrammed from control fibroblasts by Sendai virus carrying Yamanaka factors and maintained in Swaroop lab in National Eye Institute, National Institutes of Health, United States</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="top">LCA-2-clone F</td><td align="left" valign="top">PMID: 28700940</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-RHO (mouse monoclonal)</td><td align="left" valign="top">Gift of Dr. Robert Molday, University of British Columbia</td><td align="left" valign="top"/><td align="left" valign="top">IF(1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-OPN1SW (Goat polyclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">Cat#: sc-14363</td><td align="left" valign="top">IF(1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-GT335 (Mouse monoclonal)</td><td align="left" valign="top">AdipoGen</td><td align="left" valign="top">Cat#: AG-20B- 0020</td><td align="left" valign="top">IF(1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Rootletin (Chicken polyclonal)</td><td align="left" valign="top">PMID: 12427867</td><td align="left" valign="top"/><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-ARL13B (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#: 17711–1-AP</td><td align="left" valign="top">IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-OPN1LMW (Rabbit polyclonal)</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">Cat#: AB5405</td><td align="left" valign="top">IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CEP290 (Rabbit monoclonal)</td><td align="left" valign="top">Bethyl laboratories</td><td align="left" valign="top">Cat#: A301-659A</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-GAPDH (Mouse monoclonal)</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">Cat#: G8795</td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-PDE6b (Rabbit polyclonal)</td><td align="left" valign="top">PMID: 33107904</td><td align="left" valign="top"/><td align="left" valign="top">IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Synaptophysin (Mouse monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab8049</td><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-p62 (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab109012</td><td align="left" valign="top">IF (1:200) WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-LC3A/B (D3U4C) (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="char" char="." valign="top">12741</td><td align="left" valign="top">For human retinal organoids, WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-LC3B (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab51520</td><td align="left" valign="top">For mouse retina, WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-b-Actin (Mouse monoclonal)</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">A5316</td><td align="left" valign="top">WB (1:5000-1:10000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-20S (Rabbit polyclonal)</td><td align="left" valign="top">Enzo Life Sciences</td><td align="left" valign="top">BML-PW8155-0100</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-IFT88 (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="char" char="ndash" valign="top">13967–1-AP</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-BBS6 (Rabbit polyclonal)</td><td align="left" valign="top">Michel Leroux</td><td align="left" valign="top">#17</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CEP164 (Rabbit polyclonal)</td><td align="left" valign="top">GeneTex</td><td align="left" valign="top">GTX85298</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-OFD1 (Rabbit polyclonal)</td><td align="left" valign="top">Thermo</td><td align="left" valign="top">PA5-115684</td><td align="left" valign="top">WB (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-HDAC6 (Rabbit polyclonal)</td><td align="left" valign="top">Abgent</td><td align="left" valign="top">AP1106A</td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-RP1 (Chicken polyclonal)</td><td align="left" valign="top">PMID: 11773008</td><td align="left" valign="top"/><td align="left" valign="top">IF (1:2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Bassoon (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="char" char="." valign="top">6897 S</td><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CHX10 (Sheep polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab16141</td><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-PKCa (Rabbit monoclonal)</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">MA1-157</td><td align="left" valign="top">IF (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CRALBP (Mouse monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab15051</td><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-GFAP (Rabbit polyclonal)</td><td align="left" valign="top">Dako</td><td align="left" valign="top">Z0334</td><td align="left" valign="top">IF (1:500) WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Calretinin (Rabbit monoclonal)</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">MAB1568</td><td align="left" valign="top">IF (1:200)</td></tr><tr><td align="left" valign="top">Commercial kits</td><td align="left" valign="top">Proteasome 20 S Activity Assay Kit</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">MAK172-1KT</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Reserpine</td><td align="left" valign="top">Sigma Aldrich</td><td align="char" char="." valign="top">06859</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">MRT68921</td><td align="left" valign="top">Sigma Aldrich</td><td align="left" valign="top">SML1644</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Lys05</td><td align="left" valign="top">Sigma Aldrich</td><td align="left" valign="top">SML2097</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Chloroquine</td><td align="left" valign="top">Sigma Aldrich</td><td align="left" valign="top">C6628</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Hydroxychloroquine</td><td align="left" valign="top">Sigma Aldrich</td><td align="left" valign="top">H0915</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">ROC-325</td><td align="left" valign="top">Selleck</td><td align="left" valign="top">S8527</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Bafilomycin A1</td><td align="left" valign="top">Sigma Aldrich</td><td align="char" char="ndash" valign="top">19–148</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Tubastatin A</td><td align="left" valign="top">Sigma Aldrich</td><td align="left" valign="top">SML0044</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Photoshop CC 2019</td><td align="left" valign="top">Adobe</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">FIJI</td><td align="left" valign="top">FIJI</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">R</td><td align="left" valign="top">R-core team</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Biowulf Linux cluster</td><td align="left" valign="top">National Institutes of Health</td><td align="left" valign="top"/><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://biowulf.nih.gov">http://biowulf.nih.gov</ext-link></td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">DAPI stain</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">D1306</td><td align="left" valign="top">(1 µg/mL)</td></tr></tbody></table></table-wrap></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83205.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Zhongjie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.14.22279917" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.14.22279917"/></front-stub><body><p>This work provides an important pipeline for high-throughput screening platform to be used for drug discovery. The current data are complete. Validation of human patients-derived iPSC clones and functional assays in mice further strengthens the current conclusion.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83205.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Fu</surname><given-names>Zhongjie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ueffing</surname><given-names>Marius</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03a1kwz48</institution-id><institution>University of Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.14.22279917">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.09.14.22279917v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Marius Ueffing (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The current study proposed a drug discovery pipeline to accelerate the process of identifying drug candidates for LCA10 patients using mouse retinal organoid for initial screening, human patient iPSC-derived retinal organoid for further testing, and then mouse mutants for in vivo validation. Reserpine was identified as the top candidate, possibly through modulating proteostasis and autophagy to promote cilium assembly. The study is with high translational value. However, the rationale using dissociated single cells from mouse retinal organoid for drug screening needs to be justified. Further validation of human patient-derived iPSC clones and multiple clones to represent each patient are required. The consistency of phenotypic characteristics in human patient iPSC-derived retinal organoid needs to be reported. It was unclear if the rescued phenotypic changes were from the drug effects or a result of phenotypic variations in organoids. Functional assays in mice (ERG) could further improve the impact of the study: untreated control, treated-control, untreated mutant and treated-mutant in vivo.</p><p>Essential revisions:</p><p>1) Further validation of human patient-derived iPSC clones and multiple clones to represent each patient are required. The consistency of phenotypic characteristics in human patient iPSC-derived retinal organoid needs to be reported.</p><p>2) Functional assays in mice (ERG) could further improve the impact of the study: untreated control, treated-control, untreated mutant and treated-mutant in vivo.</p><p>3) The rationale using dissociated single cells from mouse retinal organoid for drug screening needs to be justified.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Figure 3: The number of human retinal organoids used for each experimental condition needed to be reported here. What are the differences in clinical symptoms between LCA-1 and LCA-2 patient?</p><p>2. Figure 6: The immunostaining signals could be affected by experimental procedure. In addition to the IHC results, functional tests of retinal activity would add more value into the validation of reserpine in rd16 mice.</p><p>3. Figure S5: Panel I was missing.</p><p>4. Figure S7: WT retinas shall be included to reveal inner retinal neuronal changes in rd16 mice.</p><p>5. In all figures, n number and statistics shall be included in the figure legends.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>To further improve the manuscript, the following points could be addressed:</p><p>– Are there studies showing reserpine treatment in other retinal diseases? Please discuss.</p><p>– What about the use of DMSO as a vehicle control? Also, does DMSO cause certain side effects?</p><p>– According to Figure 3 and FS5, three time points were considered as reserpine treatments. Please explain additional reserpine treatments in the text. It is also not clear why the authors choose different days for the treatment for the RNA-seq experiment (from D117 to D150).</p><p>– Figure 3: Quantification of rhodopsin and opsin is required, as done in Figure 2.</p><p>– What about toxicity to monitor degeneration of photoreceptors in organoid and mouse models? Cell death assays may help to understand this. Otherwise, it would be difficult to say anything about photoreceptor cell death.</p><p>– Figure 6D- Quantification of p62 is missing. Also, please explain why WT organoids lack 20S protein expression.</p><p>– Figure S3- Analysis of fluorescence of RHO, synaptophysin, basson, and other proteins is needed to detect variability between samples.</p><p>– Did the authors check ubiquitin as a marker for UPS in organoids or mouse model before and after treatment?</p><p>– Why was 40 µM of reserpine chosen for intravitreal injection into mouse retina? Were other concentrations tested?</p><p>– &quot;To experimentally examine the role of PN in survival of LCA10 photoreceptors, we supplemented organoid cultures with various autophagy inhibitors (MRT68921, Lys05, chloroquine, hydroxychloroquine, ROC-325) that target different steps of the autophagy pathway (Figure S6A)&quot;. Please indicate on which day and for how long the organoids were treated.</p><p>– There are three different bands in LC3 western blotting. Which band was thought to be LC3 II?</p><p>– How did the authors relate the reduced 20S expression to the increased proteasomal activity? Please explain.</p><p>– &quot;Notably, reserpine treatment significantly reduced GFAP levels that expanded to the entire retina in untreated mice (Figure S7C),..&quot; Please show quantification of GFAP.</p><p>– &quot;Consistent with the moderate response of LCA-2 patient organoids to reserpine (Figure 3B), we did not identify significant differentially expressed (DE) genes between untreated and treated groups of LCA-2 for downstream analyses (data not shown) and thereby focused only on LCA-1.&quot;. Considering LCA-1 and LCA.2 are two affected compound heterozygous children, did authors see any differences between LCA-2 to LCA-1 via RNA-seq analysis?</p><p>– Some studies show that survival of autophagy is protective in retinal degeneration. Please discuss this in the Discussion.</p><p>– Discussion: The relationship between reserpine and p62 should be presented more clearly and should be consistent with previously published work.</p><p>– Recommendations for the authors:</p><p>As written in the public review, functional assays in mice (ERG) could significantly improve the impact of the study: untreated control, treated control, untreated mutant, and treated mutant in vivo.</p><p>– the quality of the images can be improved. Each figure should be labeled in the same order (e.g., red, green, blue).</p><p>– Not all antibodies are listed in the antibody list. Please complete.</p><p>–Figure 4 B: Please label the gene names and explain the heat map showing the up-regulated/down-regulated genes. The red rectangle highlights the &quot;proteasome&quot; factor. Highlight the rectangle there.</p><p>– Figure S5: The labels in the figure are not visible. Please update them.</p><p>Figure S6 B and D: Please analyze rhodopsin and S-opsin. Improve the quality of the images.</p><p>– Figure S7: Please use high quality images.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>First, it is difficult to determine if the proper validations and controls were used for this paper since the methods section describing iPSC derivation refers to Shimada et al. 2017. And the methods description in that paper was not thorough.</p><p>The authors must provide proper karyotype characterization of all iPSC lines used in this study, including mouse lines. No conclusions can be made until the iPSC lines have been shown to have normal chromosomal structure. Chromosomal abnormalities are very common in iPSC derivation.</p><p>For the patient derived iPSCs it does not appear that the authors used multiple iPSC clones to represent each patient. This is standard practice for patient iPSC modeling and especially relevant in this manuscript as the authors did not detect differentially expressed genes in the LCA2 patient retinal organoids.</p><p>Since the LCA2 retinal organoids did not show gene expression differences even though they do show structural differences, so there is not enough data to conclude that the gene expression differences observed in LCA1 were due to the CEP290 mutation. Differences in gene expression could be due to differences in iPSC derivation. Authors need to show repeatable differences in multiple independently derived iPSC clones from the same patient, or multiple patients, or correct the mutation using CRISPR editing to show rescue.</p><p>The experiment as it stands is not controlled sufficiently enough to make conclusions.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83205.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Further validation of human patient-derived iPSC clones and multiple clones to represent each patient are required. The consistency of phenotypic characteristics in human patient iPSC-derived retinal organoid needs to be reported.</p></disp-quote><p>We agree that validation of the patient induced pluripotent stem cell (iPSC) lines and the variability of clones is a concern for the drug effects on the derived retinal organoids. Therefore, we have now reported the karyotypes (Figure 1—figure supplement 1) and other quality controls (Materials and methods) in the manuscript and tested reserpine on retinal organoids derived from 2 clones of each (a total of 4) of LCA1 and LCA2 patients. As suggested by the reviewers, we quantified the fluorescence intensity of rod marker rhodopsin staining in multiple sections of at least two batches of differentiation in the treatment of reserpine and other relevant compounds to better present the variations. Reserpine treatment significantly increased the fluorescence intensity of rhodopsin in retinal organoids differentiated from multiple lines (Figure 3C). Although the increase of rhodopsin fluorescence intensity was not significant in some clones treated with reserpine, which could be due to their large variations, an obvious positive trend could still be observed in these organoids (Figure 3—figure supplement 2). We have also included immunoblotting analyses of key autophagy and primary cilium markers in untreated and treated LCA2 patient organoids (Figure 5—figure supplement 3). A consistent trend of changes of these markers between two patients was observed, indicating that the mechanisms of action of reserpine proposed in this manuscript could be applied for different <italic>CEP290</italic>-LCA patients regardless of the responsiveness to reserpine.</p><disp-quote content-type="editor-comment"><p>2) Functional assays in mice (ERG) could further improve the impact of the study: untreated control, treated-control, untreated mutant and treated-mutant in vivo.</p></disp-quote><p>We agree and have performed ERG experiments as suggested by the reviewer. The CEP290 disease in <italic>rd16</italic> mouse retina has a very early onset. Because of technical challenges in intravitreal injections in the small neonatal or early postnatal mouse eye, we performed two intravitreal injections at P7 and P14 and electroretinogram (ERG) data from untreated and treated wild type (WT) and <italic>rd16</italic> mice are now included in the manuscript (Figure 6—figure supplement 2 and Figure 6D). No significant differences were found in the morphology of rod and cone photoreceptors (Figure 6—figure supplement 2) or scotopic or photopic a-/b- waves (Figure 6—figure supplement 2) between WT retina injected with vehicle (DMSO) and reserpine, suggesting reserpine did not impact WT retina.</p><p><italic>Rd16</italic> mice injected twice, at P7 and P14, with reserpine showed a marginally improved scotopic a-wave and a significantly higher b-wave, suggesting an improvement of rod photoreceptors in <italic>rd16</italic> mice by reserpine treatment (Figure 6D). No significant differences were detected in photopic a- or b- waves between untreated and treated <italic>rd16</italic> mice, likely because the cones are affected later.</p><p>Further development of therapies using reserpine and related molecules would require extensive optimization of dosage and delivery methods as well as toxicity studies. These are now subject of future investigations.</p><disp-quote content-type="editor-comment"><p>3) The rationale using dissociated single cells from mouse retinal organoid for drug screening needs to be justified.</p></disp-quote><p>Medium to high-throughput screening strategies require easy and consistent assay parameters at least during primary screens. We screened over 6000 small molecules at 11 different concentrations with duplicates.</p><p>Numerous studies from our and other labs have shown an early effect of the disease mutation on rod photoreceptors. We could visualize rods by GFP signal that was driven by the <italic>Nrl</italic> promoter. However, based on our flow cytometry analyses, <italic>rd16</italic> iPSC-derived retinal organoids show substantial variations in <italic>Nrl</italic>-GFP signal, which could mask positive hits in the primary screens. We therefore used single-cell cultures dissociated from <italic>rd16</italic> iPSC-derived retinal organoids for primary drug screens to ensure the presentation of each compound to homogenous cells.</p><p>Due to the large scale of screens, it is not feasible to perform this manually and the cells were dispensed into culture plates by a semi-automatic electronic dispenser. Mouse retinal organoids are too big to be dispensed and would be damaged during the process. Also, the screening was performed in 1536-well plates, and each well is too small to accommodate even a single mouse organoid. Therefore, we performed the screens using single cells.</p><p>We have clarified this in the text.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Figure 3: The number of human retinal organoids used for each experimental condition needed to be reported here. What are the differences in clinical symptoms between LCA-1 and LCA-2 patient?</p></disp-quote><p>Each image was representative of at least 3 batches of differentiation, each of which had at least 2 organoids. This information was mentioned in Methods and Materials, but we have now included it in the figure legends as well. We also added a violin plot showing the fluorescent intensity of rhodopsin staining to better present the variations in each experiment (Figure 3C and Figure 3—figure supplement 2).</p><p>LCA-1 and LCA-2 patient displayed comparable clinical symptoms including almost undetectable full field electroretinogram, nystagmus (eye movements), poor pupillary light responses, and oculodigital reflex. Clinical phenotypes of <italic>CEP290</italic>-LCA patients have been described previously in many publications by Prof. Samuel G. Jacobson (U. Penn), who sadly passed away a few weeks ago. Only the retinal phenotypes will be represented in the organoids, as predicted, and likely show an early stage in disease pathogenesis.</p><p>Variability in drug response is common in human experiments because of extensive genetic variations. The response to reserpine in retinal organoids could be caused by variations in derivative iPSC lines, differentiation conditions, and/or intrinsic genetic variants between the two patients.</p><disp-quote content-type="editor-comment"><p>2. Figure 6: The immunostaining signals could be affected by experimental procedure. In addition to the IHC results, functional tests of retinal activity would add more value into the validation of reserpine in rd16 mice.</p></disp-quote><p>We thank the reviewers for the suggestions. The rescue of photoreceptors by reserpine on <italic>rd16</italic> mice was not just shown by immunostaining but primarily by the increase of outer nuclear layer thickness and the improvement of the outer segment biogenesis.</p><p>To strengthen our conclusions, we have now performed functional tests and shown that reserpine treatment increased scotopic a-wave marginally and b-wave significantly, suggesting an improvement of rod photoreceptor function (Figure 6D).</p><disp-quote content-type="editor-comment"><p>3. Figure S5: Panel I was missing.</p></disp-quote><p>We apologize. Due to the limited space in the Figure (as is generally the case), Panel I was placed next to Panel D instead of the end of the figure. This is now Figure 4—figure supplement 1 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4. Figure S7: WT retinas shall be included to reveal inner retinal neuronal changes in rd16 mice.</p></disp-quote><p>Thanks for pointing this to us. Images from WT retina are included now (Figure 6—figure supplement 3).</p><disp-quote content-type="editor-comment"><p>5. In all figures, n number and statistics shall be included in the figure legends.</p></disp-quote><p>N number and statistics are now included in the figure legends.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>To further improve the manuscript, the following points could be addressed:</p><p>– Are there studies showing reserpine treatment in other retinal diseases? Please discuss.</p></disp-quote><p>Reserpine has been reported to induce rod outer segment elongation. The systemic effects of reserpine on the modulation of outcome of intraocular pressure drug and allergic inflammation of the eye have also been reported. However, to our knowledge, there are no other studies testing reserpine in other retinal diseases. We have now briefly mentioned these in the Discussion.</p><disp-quote content-type="editor-comment"><p>– What about the use of DMSO as a vehicle control? Also, does DMSO cause certain side effects?</p></disp-quote><p>The percentage of DMSO used in the study is 0.4% (v/v) or less. In cell culture experiments, 0.5% DMSO as the final concentration has been used widely without cytotoxicity. DMSO is generally considered as non-toxic (in rat retina as high as 2%) and widely used as a vehicle control for intravitreal injections. We performed intravitreal injections of 0.4% DMSO in wild type and <italic>rd16</italic> mouse retina and did not observe any side effects by histologic evaluation or ERG (wild type data with DMSO and reserpine injections are shown in Figure 6—figure supplement 2). No systemic toxicity has been observed in the injected mice either.</p><disp-quote content-type="editor-comment"><p>– According to Figure 3 and FS5, three time points were considered as reserpine treatments. Please explain additional reserpine treatments in the text. It is also not clear why the authors choose different days for the treatment for the RNA-seq experiment (from D117 to D150).</p></disp-quote><p>We have now provided more details in the Methods and Material to explain the two reserpine treatments. To evaluate the effect of reserpine, the organoids were harvested 10 days after the third treatment to allow sufficient time for drug actions. The purpose of the RNA-seq experiments is to identify the signaling pathways modulated by reserpine. In this case, we harvested the organoids immediately after the third drug treatment to avoid compounding secondary effects.</p><disp-quote content-type="editor-comment"><p>– Figure 3: Quantification of rhodopsin and opsin is required, as done in Figure 2.</p></disp-quote><p>We thank the reviewers for suggestions. A violin plot with fluorescence intensity of rhodopsin is now provided at Figure 3C and Figure 3—figure supplement 2. As LCA patient organoids did not have dramatic phenotypes on cone photoreceptors, we did not quantify cone opsins and have modified the text accordingly.</p><disp-quote content-type="editor-comment"><p>– What about toxicity to monitor degeneration of photoreceptors in organoid and mouse models? Cell death assays may help to understand this. Otherwise, it would be difficult to say anything about photoreceptor cell death.</p></disp-quote><p>Here, we have focused primarily on rod photoreceptor survival as an assay and started treatment before cell death occurs (i.e., day 107 in organoids and P7 in mouse retina). For human retinal organoids, no dramatic difference of outer nuclear layer thickness on patient organoids have been observed by us or reported by other groups at this stage. Cell death in <italic>rd16</italic> mouse retina is detected at or after P12. Therefore, the increase of outer nuclear layer observed in reserpine-treated retina suggests an inhibition of photoreceptor cell death as post-mitotic rod photoreceptors do not proliferate at this stage.</p><p>We will be performing extensive dosage and drug toxicity experiments as part of our future investigations.</p><disp-quote content-type="editor-comment"><p>– Figure 6D- Quantification of p62 is missing. Also, please explain why WT organoids lack 20S protein expression.</p></disp-quote><p>We have now added quantification of p62 puncta (Figure 7B). The 20S protein expression was from WT mice but not organoids. 20S protein is present in WT retinal lysate but detected in a much lower amount compared to the <italic>rd16</italic> ones. Overexposure of the immunoblotting membrane could reveal the presence of 20S expression. In concordance, we had previous shown the expression of 20S proteosome in RNA-seq data of rod photoreceptors (Kim et al., <italic>Cell Reports</italic>, 2016).</p><disp-quote content-type="editor-comment"><p>– Figure S3- Analysis of fluorescence of RHO, synaptophysin, basson, and other proteins is needed to detect variability between samples.</p></disp-quote><p>We have now included the quantification of rhodopsin staining in reserpine and other compound treatments as reserpine mainly acts on rod photoreceptors. We did not quantify the immunostaining of other retinal cell types as the high variation of them make it technically challenging and labor intensive to reach a solid conclusion, yet we note that it is not the main goal of the manuscript. We performed immunostaining of other retinal or structural markers only to demonstrate that reserpine did not largely impact other retinal structures or cell types. We have modified the text and removed the descriptive comparison of other retinal cell types or structure between untreated and treated organoids.</p><disp-quote content-type="editor-comment"><p>– Did the authors check ubiquitin as a marker for UPS in organoids or mouse model before and after treatment?</p></disp-quote><p>We did not compare ubiquitin level as ubiquitin-labeled proteins could also be targeted by autophagy and are not specific to UPS.</p><disp-quote content-type="editor-comment"><p>– Why was 40 µM of reserpine chosen for intravitreal injection into mouse retina? Were other concentrations tested?</p></disp-quote><p>In the primary screens, the EC<sub>50</sub> of reserpine was around 20 uM. We doubled the concentration for injection to account for the potential loss of reserpine during the procedures. As we observed a rescue effect of reserpine, we used the same concentration for all experiments at this stage as animal work takes a long time. No other concentrations of reserpine were tested in the current study.</p><p>We will be performing extensive dosage and drug toxicity experiments as part of our future investigations.</p><disp-quote content-type="editor-comment"><p>– &quot;To experimentally examine the role of PN in survival of LCA10 photoreceptors, we supplemented organoid cultures with various autophagy inhibitors (MRT68921, Lys05, chloroquine, hydroxychloroquine, ROC-325) that target different steps of the autophagy pathway (Figure S6A)&quot;. Please indicate on which day and for how long the organoids were treated.</p></disp-quote><p>Treatment of other autophagy inhibitors was performed the same way as reserpine treatment. We have now provided this information in the figure and text.</p><disp-quote content-type="editor-comment"><p>– There are three different bands in LC3 western blotting. Which band was thought to be LC3 II?</p></disp-quote><p>We apologize for the confusion. The lower band is LC3-II. We have added labels in our immunoblotting images.</p><disp-quote content-type="editor-comment"><p>– How did the authors relate the reduced 20S expression to the increased proteasomal activity? Please explain.</p></disp-quote><p>The expression level of 20S was consistently elevated in patient organoids and <italic>rd16</italic> mouse retina, yet the chymotrypsin-like activities were lower compared to the control, suggesting the higher expression of 20S protein level was to compensate for their low activity. While reserpine treatments partially restored proteostasis and increased 20S activity, the high level of 20S was not needed and thus was reduced.</p><p>We have added this in the Discussion.</p><disp-quote content-type="editor-comment"><p>– &quot;Notably, reserpine treatment significantly reduced GFAP levels that expanded to the entire retina in untreated mice (Figure S7C),..&quot; Please show quantification of GFAP.</p></disp-quote><p>The expression level of GFAP is now shown by immunoblotting analyses and quantification (Figure 6—figure supplement 3).</p><disp-quote content-type="editor-comment"><p>– &quot;Consistent with the moderate response of LCA-2 patient organoids to reserpine (Figure 3B), we did not identify significant differentially expressed (DE) genes between untreated and treated groups of LCA-2 for downstream analyses (data not shown) and thereby focused only on LCA-1.&quot;. Considering LCA-1 and LCA.2 are two affected compound heterozygous children, did authors see any differences between LCA-2 to LCA-1 via RNA-seq analysis?</p></disp-quote><p>We did observe differences in RNA-seq data between LCA-1 and LCA-2. Although the differentially expressed genes compared to the control were largely similar between the two patients, the expression level and the peak of appearance of these DE genes was different. This could also be one explanation as to why reserpine only showed moderate effect on LCA-2 organoids.</p><disp-quote content-type="editor-comment"><p>– Some studies show that survival of autophagy is protective in retinal degeneration. Please discuss this in the Discussion.</p></disp-quote><p>The effect of autophagy on retinal degeneration depends on the cause of the disease. Balance of proteostasis pathways is critical for cell survival. In addition, we argue that, regardless of autophagy activation or inhibition, it was the clearance of accumulative proteins that rescues photoreceptors. We have modified the Discussion to emphasize this point.</p><disp-quote content-type="editor-comment"><p>– Discussion: The relationship between reserpine and p62 should be presented more clearly and should be consistent with previously published work.</p></disp-quote><p>To our knowledge, we had a consistent outcome of p62 accumulation as previous studies. We have modified the Discussion to discuss their relationship and subsequent impact on proteostasis.</p><disp-quote content-type="editor-comment"><p>– Recommendations for the authors:</p><p>As written in the public review, functional assays in mice (ERG) could significantly improve the impact of the study: untreated control, treated control, untreated mutant, and treated mutant in vivo.</p></disp-quote><p>We thank the reviewer for the suggestions. As mentioned previously, we have now performed ERG experiments to compare untreated/treated WT/<italic>rd16</italic> mice. No significant differences were found between untreated and treated WT mice, suggesting the reserpine treatment did not interfere retinal functions of WT mice (Figure 6—figure supplement 2). Functional improvement of rod photoreceptors in <italic>rd16</italic> mice was revealed by marginally increased a-wave and significantly increased b-wave (Figure 6D).</p><disp-quote content-type="editor-comment"><p>– the quality of the images can be improved. Each figure should be labeled in the same order (e.g., red, green, blue).</p></disp-quote><p>We used high-quality images for all our figures. The obscure images in the supplemental figures could be due to the process of generation of the PDF file. We have improved our way to present the figures. We also modified the order of each channel across all images for improved consistency.</p><disp-quote content-type="editor-comment"><p>– Not all antibodies are listed in the antibody list. Please complete.</p></disp-quote><p>We apologize and have now completed the antibody list (Key Resources Table).</p><disp-quote content-type="editor-comment"><p>–Figure 4 B: Please label the gene names and explain the heat map showing the up-regulated/down-regulated genes. The red rectangle highlights the &quot;proteasome&quot; factor. Highlight the rectangle there.</p></disp-quote><p>The heatmap in Figure 4B summarizes the expression of 355 genes responding to reserpine treatment and thus names cannot be added due to the large number of genes. We have now included Table Supplement 1 with details of the differentially expressing genes. Additionally, Figure 4C now has names of the top differentially expressed genes labeled in the volcano plot. We also added a red rectangle highlighting Proteasome.</p><disp-quote content-type="editor-comment"><p>– Figure S5: The labels in the figure are not visible. Please update them.</p></disp-quote><p>We thank the reviewer for pointing this out. We have adjusted the size of the figure to improve legibility.</p><disp-quote content-type="editor-comment"><p>Figure S6 B and D: Please analyze rhodopsin and S-opsin. Improve the quality of the images.</p></disp-quote><p>We have now quantified the fluorescence intensity of rhodopsin in the images and improved the export of images. S-opsin staining did not show morphological changes and is not the focus of the manuscript. We have modified the text accordingly.</p><disp-quote content-type="editor-comment"><p>– Figure S7: Please use high quality images.</p></disp-quote><p>Our previous way of generation of the PDF file for supplemental figures may have blurred the images. We have now improved our way to generate the PDF.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>First, it is difficult to determine if the proper validations and controls were used for this paper since the methods section describing iPSC derivation refers to Shimada et al. 2017. And the methods description in that paper was not thorough.</p><p>The authors must provide proper karyotype characterization of all iPSC lines used in this study, including mouse lines. No conclusions can be made until the iPSC lines have been shown to have normal chromosomal structure. Chromosomal abnormalities are very common in iPSC derivation.</p><p>For the patient derived iPSCs it does not appear that the authors used multiple iPSC clones to represent each patient. This is standard practice for patient iPSC modeling and especially relevant in this manuscript as the authors did not detect differentially expressed genes in the LCA2 patient retinal organoids.</p><p>Since the LCA2 retinal organoids did not show gene expression differences even though they do show structural differences, so there is not enough data to conclude that the gene expression differences observed in LCA1 were due to the CEP290 mutation. Differences in gene expression could be due to differences in iPSC derivation. Authors need to show repeatable differences in multiple independently derived iPSC clones from the same patient, or multiple patients, or correct the mutation using CRISPR editing to show rescue.</p><p>The experiment as it stands is not controlled sufficiently enough to make conclusions.</p></disp-quote><p>We have now provided more details on iPSC derivation, maintenance, quality control, and differentiation. Karyotypes of all mouse and human iPSC lines were provided in Figure 1—figure supplement 1. The karyotyping analysis was independently performed by experienced personnel in the Comparative Cytogenetics Core Facility of National Cancer Institute. Cells were harvested according to the standard protocol and prepared for G-band stain. Fifteen unique metaphases were analyzed. Retinal organoids were generated using iPSC lines within 10 passages of test cells. As shown in Figure 1—figure supplement 1, all mouse and human iPSC lines exhibited normal karyotypes except <italic>rd16</italic> line 2, which had one missing sex chromosome. As one missing sex chromosome should not have dramatic impact on disease-associated phenotypes, we kept <italic>rd16</italic> line 2 to confirm the phenotypes of <italic>rd16</italic> organoids but used <italic>rd16</italic> line 1, which was karyotypically normal, for high-throughput screening and secondary assays.</p><p>We have now tested reserpine on retinal organoids derived from 2 clones of each of LCA1 and LCA2. We also quantified the fluorescence intensity of rod marker rhodopsin staining in multiple sections of at least two batches of differentiation (Figure 3C and Figure 3—figure supplement 2). A marginally or significantly increase of rhodopsin fluorescence intensity could be observed in retinal organoids differentiated from multiple clones and cell lines.</p><p>In our manuscript, we used retinal organoids differentiated from <italic>CEP290</italic>-LCA as a model to identify drugs to maintain photoreceptor survival. We hypothesized that reserpine treatment is not directly rescuing CEP290 function but works downstream to keep the cells alive, and we performed RNA-seq to identify the pathways that might be implicated in this process. Our data provided the clues that we pursued to understand the mechanism. We performed additional assays to validate the dysregulated proteostasis pathway identified in RNA-seq data. Further validation of other pathways in different models are needed but beyond the scope of this manuscript. Therefore, we do not believe that additional RNA-seq on multiple cell lines or corrected CEP290 clones will provide further insights into how reserpine treatment leads to rod photoreceptor survival and maintenance of function.</p><p>As reserpine does not act as a transcription factor, the change of gene profiles upon reserpine treatment could vary in time and intensity, which could explain the few differentially expressed genes observed in LCA-2. The differentially expressed genes being shown here are between untreated and treated patient organoids but not between control and patients. Notably, although LCA2 did not show sufficient differentially expressed genes, dysregulation of proteostasis pathway is still observed in LCA patients and the action mechanism of reserpine could be validated in LCA2 (Figure 5—figure supplement 3), further strengthening our findings.</p><p>Our manuscript has focused on identification of drug candidates for <italic>CEP290</italic>-LCA disease. As mentioned previously, “We would also like to respectfully point out that after the initial medium-high throughput small molecule drug screening using <italic>rd16</italic> rod photoreceptors, we performed secondary screening of selected compounds using <italic>rd16</italic> mouse retinal organoids. Then, we performed reserpine (lead compound) treatment studies using human retinal organoids from CEP290-LCA patients and in vivo in <italic>rd16</italic> mouse retina. We have now added additional experiments using human patient organoids as well as functional data from <italic>rd16</italic> mouse. Thus, reserpine has gone through 4 different screens and validations. The functional recovery of rod photoreceptors in reserpine-treated <italic>rd16</italic> mice and comparable action mechanisms of reserpine on in vivo <italic>rd16</italic> mice demonstrates the success of our drug discovery pipeline and the validations of our findings.</p></body></sub-article></article>